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ABSTRACT 
Rheumatic diseases are chronic conditions that affect a substantial proportion of the adult 
population. Likewise, cancer is a major threat to public health, and the leading cause of death 
worldwide. Chronic inflammation is a key component in both rheumatic disease and cancer, 
and during the last decades, major treatment advances have been made in both of these fields. 
Due to the high prevalence of cancer in the age groups typically affected by rheumatic 
disease, it is a common comorbidity. Disentangling the association between rheumatic 
disease and cancer is complicated by the fact that cancer risk and prognosis can be affected 
by both aberrations related to host defense in rheumatic disease, as well as the treatment. For 
example, we know that risk of lymphoma is directly linked to disease severity in RA, but this 
does not preclude a further risk increase by RA treatment. In this thesis we capitalized on the 
rich data sources of Swedish national registers. Patients with rheumatic disease and matched 
comparators were identified, and by linkage to other registers, treatments, comorbidities, and 
other data were added. This allowed for comparisons by treatment and other characteristics 
within patient populations, and let us benchmark risks to that of the general population. 
Studies I and II investigated the risk of cervical neoplasia in RA, and SLE, respectively. In 
Study I, the aim was to assess if there was an increased risk of cervical neoplasia in RA 
overall, and if TNFi-treatment increased this risk. In Study II we wanted to investigate the 
risk of cervical neoplasia in SLE overall, and if this risk differed between treatment-defined 
subgroups. We tried to separate the risk associated with the respective disease itself, from that 
of any potential risk carried by immunosuppressant treatment of RA and SLE. In these 
studies, we considered factors which were associated with the exposure and the outcome, and 
could act as confounders of the risk of rheumatic disease/treatment on cervical neoplasia. We 
found that there was an increased risk of cervical neoplasia overall in both RA and SLE, and 
that these risks were further increased in subsets treated with TNFi in RA, and other 
immunosuppressants in SLE, although the extent to which this was a direct effect of the 
treatments was hard to disentangle. Study III investigated the risk of incident cancer, overall 
and by cancer site, in RA patients treated with TNFi and other bDMARDs. Five cohorts of 
RA patients initiating treatment with tocilizumab, abatacept, rituximab, and a first or second 
TNFi, were assembled, as well as a csDMARD treated cohort. With the exception of an 
increased risk of squamous cell skin cancer in abatacept-treated, there were no significant risk 
differences between bDMARD-, and csDMARD treated RA. We concluded that short- to 
medium-term use of tocilizumab, abatacept, rituximab, or TNFi drugs seems to be safe with 
regard to risks of incident cancer. Study IV investigated the association between RA and 
breast cancer, as well as anti-hormonal breast cancer treatment. In a matched cohort design, 
we replicated previous findings of a 20% decreased risk of breast cancer among women with 
RA. In a case-control design, we found that the risk of RA in women with breast cancer was 
also decreased. We found no evidence to support that anti-hormonal breast cancer treatment 
increased the risk of RA. Although we were able to take potentially important confounders 
into account, we could not disentangle the roots of the negative association between RA and 
breast cancer, which led us to conclude that it might be due to other shared factors. 
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1 BACKGROUND 
1.1 INTRODUCTION 
Rheumatology is a field of medicine that involves the treatment of rheumatic disease, i.e. 
inflammatory joint disease and inflammatory systemic disease. The immune system protects 
the host from foreign pathogens, such as bacteria, viruses or parasites. Autoimmune 
conditions originate from an abnormal immune response, where the host reacts by attacking 
itself. This results in ensuing, often chronic, inflammation. In rheumatic disease, most parts of 
the body can be affected, but often it involves the musculoskeletal system, such as the joints. 
The chronic inflammation can cause pain and swelling, and, especially if left untreated, 
chronic disability and premature death. Chronic inflammation and immunity is also a key 
component in cancer development (1). Untreated inflammation and immunological 
aberrations in rheumatic disease might thus promote tumorigenesis. Conversely, treatment of 
rheumatic disease, which typically involves suppression or modulation of the immune 
system, can lower host defense against incipient tumors. Some of the agents used in 
rheumatology are also used in the treatment of certain forms of cancer, but can themselves be 
associated with increased cancer risks (2, 3). 
1.2 RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that typically 
affects the small joints in hands and feet. In Sweden, the incidence is about 41 cases per 
100,000 person years with a marked female predominance (4). The debut is often insidious, 
with fatigue, morning stiffness, and symmetrical joint pain and swelling of the small distal 
joints. Although symptoms arising from local inflammation in the joints is the most 
prominent feature, RA is a systemic disease. Constitutional symptoms e.g. fever, malaise, and 
weight loss, are common and arise from systemic inflammation. Other extra-articular 
manifestations, such as serositis, and cutaneous vasculitis, also feature in RA (5). While 
advances in understanding the pathogenesis of RA have been made, the etiology is still 
unclear. Autoimmunity, as demonstrated by antibodies against anti-citrullinated proteins 
(ACPA), can predate clinical symptoms of RA by decades (6, 7). Identified genetic factors 
include an association with human leukocyte antigen DR4, and the heritability of RA has 
been estimated at about 40%, with a higher heritability for ACPA-positive RA (8). Cigarette 
smoking doubles the risk of developing RA, and is particularly associated with ACPA-
positive RA, while other environmental risk factors are not well established (9-11). Although 
laboratory analyses such as C-reactive protein (CRP), rheumatoid factor, and ACPA, help in 
diagnosing the disease, RA is still a clinical and criteria-guided diagnosis. The latest 
classification criteria aimed at facilitating early diagnosis of RA (12). Although treatment 
advances have been made, RA is a chronic disease that still causes much suffering and 
disability. Patients with RA are at increased risk of several comorbid conditions, most 
importantly cardiovascular disease, but also certain types of malignancies and infections (13). 
These conditions contribute to the increased mortality that is still present in RA. (14). 
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1.3 SYSTEMIC LUPUS ERYTHEMATOSUS  
Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease that 
primarily affects women. The prevalence in Sweden is approximately 46 to 85 per 100,000 
adults (15). The phenotype of SLE varies from mild disease, mainly affecting skin and joints, 
to severe organ destructing disease. Analogous to RA, there are no diagnostic criteria, but 
classification criteria developed for research purposes can help in diagnosing the disease (16). 
Organs that are often involved in SLE include joints, skin, kidneys, lungs, heart, the central 
nervous system, and the circulatory system. The diverse clinical presentation of the disease 
can pose a challenge to the clinician in both diagnosis and treatment. Furthermore, SLE is 
associated with several comorbidities, e.g. cardiovascular disease, cancer, osteoporosis and 
infections (17, 18). The etiology of the disease is not clear but is known to involve genetic 
factors, the heritability has been estimated at 45%, similar to that of RA (19). Environmental 
risk factors such as sunlight exposure, EBV infection, and smoking have also been identified 
(20, 21). SLE is associated with the production of many autoantibodies. Antinuclear 
antibodies are present in more than 90% of patients, among these the highly SLE-specific 
anti-double-stranded DNA antibodies present in 70% of SLE-patients, but only in 0.5% of 
healthy controls (22). Apart from these antibodies, SLE is associated with numerous 
immunological aberrations involving both innate and adaptive immunity (23). The fact that 
SLE is much more common in women than men, and that it often presents during the 
reproductive years, suggests that hormonal factors might be involved. This was supported by 
a randomized controlled trial (RCT), which showed that women given hormonal replacement 
therapy (HRT) were more likely to experience flares of the disease, although the flares were 
mostly mild (24). Also, the Nurses’ Health Study found that hormonal factors such as early 
age at menarche, oral contraceptive use, early age at menopause, and HRT were all risk 
factors for developing SLE (25). Furthermore, as opposed to women with RA, women with 
SLE often experience a flare during both pregnancy and the puerperium (26). 
1.4 TREATMENT 
The current paradigm in the treatment of RA is that aggressive treatment should be 
introduced early and then be escalated in pursuit of clinical remission. We have no means of 
healing damaged joints, but if disease progression can be halted at an early stage, joint 
damage and disability can be prevented. Pharmacological treatment of RA mainly involves so 
called disease modifying anti-rheumatic drugs (DMARDs), corticosteroids, and non-steroidal 
inflammatory drugs (NSAID) (27). Systemic corticosteroids are effective in reducing 
inflammation and relieving symptoms, and may halt disease progression, but are associated 
with numerous side effects. They are therefore often part of the initial treatment strategy, and 
used as bridge-therapy or to treat flares, but the goal is to minimize the use of these agents. 
DMARDs decrease inflammation and slows disease progression as measured 
radiographically. Traditional small molecule DMARDs including agents such as 
methotrexate, sulfasalazine, and hydroxychloroquine, will from here on be referred to as 
conventional synthetic DMARDs (csDMARDs). Methotrexate is the anchor in RA therapy 
and is used as monotherapy, or in combination with other DMARDs and steroids. Targeted 
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protein DMARDs, such as tumor necrosis factor inhibitors (TNFi), rituximab, abatacept, 
tocilizumab, will be referred to as biologic DMARDs (bDMARDs).  
 
Figure 1.1. Number of registered bDMARD treatments initiated in RA patients in the Swedish 
Biologics Register (ARTIS) by year. KIN=Kineret (anakinra) MAB=Mabthera (rituximab) 
ORE=Orencia (abatacept) ROA=Roactemra (tocilizumab) TNFI=Tumor necrosis factor inhibitors 
 
Figure 1.2. Disease activity score (DAS28-CRP) values and health assessment questionnaire (HAQ) 
values for RA patients registered in Swedish Biologics Register (ARTIS) at start of first bDMARD.  
The introduction of bDMARDs in the late 1990’s has revolutionized the treatment of RA due 
to their ability to alleviate symptoms and slow radiographic progression. They are often used 
as a second-line therapy if the patient has not responded to csDMARD therapy, or first-line 
therapy in patients with high disease activity and unfavorable prognostic factors, and often in 
combination with a csDMARD such as methotrexate (27). TNFi were the first, and are the 
most widely used agents of the bDMARDs. TNFi has been linked with an increased risk of 
serious infection and tuberculosis (28-31). Therefore, screening for tuberculosis and hepatitis, 
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and treatment of latent tuberculosis infection, is recommended before start of TNFi therapy. 
Further pre-treatment assesments before initation of bDMARD therapy typically includes full 
blood count, as well as both kidney- and liver function,  
As mentioned, there is no reliable biomarker to diagnose RA. Likewise, there are no specific 
biomarkers to monitor disease activity. Besides clinical assessment and the patients self-
reported degree of well-being, a couple of tools have been brought forward to aid clinicians. 
The disease activity score-28 (DAS28), is a score that incorporates the number of tender and 
swollen (based on 28 pre-specified joints), patient self-assessment of disease activity, and 
laboratory markers (either erythrocyte sedimentation rate or CRP). A health assessment 
questionnaire (HAQ), is a score that includes questions concerning activities of daily life 
(32). These two scores are used to monitor disease activity and guide clinicians in treatment 
decisions, and are frequently used as endpoints in clinical studies.  
Table 1.1. Name and proposed mechanism of action for pharmaceutical agents discussed in 
this thesis 
Name Target/Proposed mechanism 
bDMARDs  
Abatacept  CTLA4-Ig  
Adalimumab  Anti-TNF α  
Anakinra Anti-IL-1 
Certolizumab pegol Anti-TNF α  
Etanercept  Anti-TNF α  
Golimumab  Anti-TNF α  
Infliximab  Anti-TNF α  
Rituximab  Anti-CD20  
Tocilizumab  Anti-IL-6 receptor  
csDMARDs and others  
Azathioprine Purine synthesis inhibitor 
Chloroquine phosphate (anti-
malarial) 
Suppression of IL-1, induce apoptosis of inflammatory 
cells and decrease chemotaxis 
Ciclosporin  Calcineurin inhibitor 
Cyclophosphamide Alkylating agent 
Methotrexate Purine metabolism inhibitor 
Gold salts  Unknown 
Hydroxychloroquine (anti-malarial) Suppression of TNF-alpha, induce apoptosis of 
inflammatory cells and decrease chemotaxis 
Leflunomide Pyrimidine synthesis inhibitor 
Mycophenolate mofetil  Purine synthesis inhibitor 
Sulfasalazine Suppression of IL-1 & TNF-alpha, induce apoptosis of 
inflammatory cells and increase chemotactic factors 
Tacrolimus Calcineurin inhibitor 
 
Pharmacological treatment of SLE mainly involves antimalarials, corticosteroids, 
csDMARDs, NSAIDs, bDMARDs (rituximab and belimumab), and other 
immunosuppressant drugs (33). The multifaceted clinical presentation of SLE is reflected in 
its treatment. Some patients that are in remission don’t need any maintenance treatment, other 
patients receive maintenance treatment with e.g. antimalarials or corticosteroids, while 
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patients that are experiencing severe flares may need potent immunosuppressant therapy. The 
treatment is generally chosen by which organ systems that are affected, and the perceived 
urgency in treating these manifestations. For example, joint manifestations are common in 
SLE, but if nephritis is present at the same time, treatment will be guided by the nephritis. 
Corticosteroids are effective in reducing inflammation, and are widely used both in the 
treatment of flares, and as maintenance therapy. However, long-term treatment with 
corticosteroids is associated with severe side-effects, and therefore the lowest possible dose, 
if any, is the target. Antimalarials are especially effective against skin, and musculoskeletal 
disease manifestations, but are also equipped with other positive long-term outcomes, and 
reduce the need for corticosteroids even in patients with more severe SLE. They are therefore 
often recommended to all SLE patients if there are no contraindications. 
1.5 CANCER 
Cancer is a group of diseases that are caused by mutations in genes that alter the function or 
expression of genes that regulate key processes in in the cell, such as growth, survival and 
senescence. These mutations are passed on to daughter cells upon cell division, and cancer 
cells are thus subject to natural selection. The hallmarks of cancer were defined by Hanahan 
et al. in 2000 as 1) self-sufficiency in growth signals 2) lack of response to growth inhibitory 
signals 3) evasion of apoptosis 4) the ability to replicate without limits 5) development of 
blood vessels 6) invasive ability 7) metabolic pathway reprogramming 8) immune system 
evasion (34). 
In Sweden, the life-time risk of developing cancer before the age of 65 is about 15%, rising to 
30% before the age of 75 (35). Although site-specific rates differ, the overall incidence in 
men and women is quite similar. The most common cancers are prostate cancer and breast 
cancer, followed by skin, colon, lung, and bladder cancer (35). Although treatment advances 
have been made, cancer is in many cases still a deadly disease. 
A large body of evidence supports the association between chronic inflammation and cancer. 
Many chronic inflammatory conditions are known to predispose the organism to cancer 
development (1). The etiological agents are in many cases infectious, such as human 
papilloma virus (HPV) infection in cervical cancer, or Helicobacter Pylori in stomach cancer. 
In other cases, the inflammatory state is caused by inhalation or ingestion of a chemical 
agent, such as in cigarette smoking and lung cancer. The immune system is needed by the 
tumor to create a suitable microenvironment in which to grow. Inflammatory cells promote 
the growth of blood vessels and supporting tissue. Furthermore, the immune system is 
essential in checking the development of cancer, and thus immunosuppression has been 
shown to promote the development of cancer. For example, recipients of a solid organ 
transplant, as well as HIV-positive patients, have an increased risk of many types of cancer 
(36). 
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1.6 RHEUMATOID ARTHRITIS AND CANCER 
Before examining risks with different anti-rheumatic therapies, an understanding of the 
baseline risk of cancer in RA is important. However, the fact that most patients receive some 
kind of immunosuppressant or immunomodulatory therapy makes it hard to determine the 
baseline risk. The risk of cancer in RA is thought to be modified by factors relating directly to 
autoimmunity and inflammation, pharmaceutical treatment of RA, and environmental factors 
shared between RA and cancer e.g. as in the case of lung cancer. The overall risk of cancer in 
RA is elevated by about 5-15% compared to the general population, although the site specific 
data show a heterogeneous picture with both increased and decreased risks (14, 37-39). At the 
typical age of RA onset (~60 years), 9% will already have a cancer in their medical history, 
and more than 20% will develop a cancer in the following 15 years (35). Considering the 
high life-time risk of developing a tumor, the high prevalence of rheumatic disease, and the 
high mortality associated with many cancers, cancer constitutes a clinically highly relevant 
field in RA. 
If we turn our attention to site-specific cancers, malignant lymphoma is the most clearly 
linked cancer, the relative risk is about doubled, but the risk has been shown to be directly 
linked to the disease activity in RA (40). The risk of lung cancer has been estimated to be 
increased by about 60%, this might be partially explained by the increased risk of RA in 
smokers. However, a large case-control study found an increased risk of lung cancer in 
patients with RA even when adjusting for smoking and asbestos exposure (41). As for 
melanoma, there is a reported 25% risk increase in RA (14). Regarding non-melanoma skin 
cancers, there seems to be a 50% increased risk in RA (42-45). However, as mentioned, 
decreased risks has also been reported. For colon cancer, the previously mentioned meta-
analysis by Simon et al. found a standardized incidence ratio (SIR) of 0.78 (95% confidence 
interval, CI 0.71-0.86) (46). It has been hypothesized that this might be due to prolonged use 
of NSAIDs in RA. 
Concerning the risk with csDMARD treatment, azathioprine has been linked to an increased 
risk of lymphoma in RA (40). This may, at least in part, be due to channeling bias. Solomon 
et al. found an increased risk of cancer among RA patients treated with methotrexate 
compared to those treated with other csDMARDs or TNFi (47). Methotrexate, which is also 
used as a chemotherapeutic agent, has been associated with a slightly increased risk of non-
melanoma skin cancer (NMSC) (48). However, most studies have found no such associations 
(49, 50). Cyclophosphamide, a drug mostly used in extra-articular RA, has been linked with 
an increased risk of several cancers (51, 52). Lastly, glucocorticoids which are widely used in 
RA, have been associated with an increased risk of both overall cancer (53), and NMSC (54). 
Although there does not seem to be a clear association between disease severity and the 
overall risk of cancer in RA (44, 55), it might be an important confounder of these site-
specific results. 
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1.7 BDMARDS AND RISK OF CANCER  
TNF was first identified in 1975 for its ability to induce rapid hemorrhagic necrosis of 
experimental malignant tumors (56). It was soon discovered that TNF was a powerful 
regulator of the immune system, and that the anticancer properties of the cytokine were just 
one of its abilities. In 1987 it was found that TNF could stimulate tumor growth by inducing 
angiogenesis (57). This and subsequent discoveries of TNF as a mediator of cancer-related 
inflammation showed that TNF could be both pro- and anti-carcinogenic. Thus when TNFi 
therapy was introduced in the late 90’s, there were well-founded uncertainties about how 
these drugs might affect carcinogenesis, tumor progression, and tumor relapse. The issue of 
drug safety was one of the key reasons clinical registers, where patients treated with TNFi 
(and later other bDMARDs) could be followed longitudinally, were established in various 
countries (58, 59). Clinically, questions such as which treatment should be offered to patients 
with a previous cancer, or if certain categories of patients should be screened for certain 
cancers, are commonplace.  
An early meta-analysis of RCTs by Bongartz et al. found a three-fold increased risk of 
cancer, which was dose dependent, in adalimumab-, and infliximab- treated RA (60). 
Limitations included possible confounding, and relative small numbers (three events in the 
placebo group) partly due to short follow-up (about three- to twelve months), and 
comparisons did not take person-time into account. Nevertheless, the worrisome results of the 
study had a great impact, and later a separate meta-analysis of etanercept RCTs also showed 
an increased, although statistically non-significant, risk of cancer compared to placebo (61). 
However, subsequent meta-analyses that have included many RCTs, including other 
indications than RA, have not revealed any increased risks of overall cancer with TNFi 
compared to csDMARDs or placebo, although Askling et al. reported a higher risk of NMSC 
(62, 63).   
Data from observational studies have mainly been reassuring. A meta-analysis, which mostly 
consisted of data from the large European biologics registers, found no increased risk of 
overall cancer, with a pooled estimate of 0.95 (95% CI 0.85-1.05) (64). Similarly, 
observational studies based on data from the US (65), Taiwan (66), and Japan (67), have 
found no association, or decreased risks, of overall cancer among TNFi-treated RA. Thus 
most of the evidence point towards no increased risk of the overall short- and medium-term 
risk of cancer with use of TNFi. TNFi is also used in other autoimmune conditions, but the 
evidence in terms of cancer risk is sparse compared to that of RA. A Danish register study 
found no significant association between TNFi and overall cancer in inflammatory bowel 
disease (68) A study from the British biologics register found no association between TNFi 
and overall cancer in patients with psoriatic arthritis, although a higher risk of NMSC was 
reported (69). 
Seeing as TNF has been used in the treatment of melanoma, there could be well-founded 
concerns about the effect of TNFi on the risk of melanoma (70). Indeed, signals of an 
increased risk of invasive melanoma with TNFi therapy arose early from both observational 
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studies and meta-analyses of RCTs (43, 71). A study from the Swedish Biologics Register 
(ARTIS) found that RA patients treated with TNFi have a 50% increased risk of invasive 
melanoma compared to bDMARD-naïve RA, although there was no increased risk of in situ 
melanoma (72). However, a large collaborative effort that collated data from several 
European registers, including ARTIS, could not confirm an increased risk of invasive 
melanoma among RA patients treated with TNFi (73).  
Wolfe et al. found a 50% increased risk of NMSC among bDMARD-treated (almost 
exclusively TNFi) RA patients compared to RA patients not treated with bDMARDs (71). 
This finding was not confirmed in two later studies from the Danish, and the British, 
biologics registers, where no statistically significant risk differences was observed comparing 
TNFi-treated RA patients versus non-treated, although 50-100% risk increases was observed 
for TNFi vs. the general population (43, 74). A study from ARTIS reported a doubled risk for 
squamous cell skin cancer in biologics-naïve RA, and a further 30% risk increase among 
TNFi-treated RA patients, but found no increased risk for basal cell skin cancer (75). Apart 
from skin cancer, TNFi has also been linked with an increased risk of lymphoma (76). 
However, most studies have shown no such association (64, 77). Since RA disease activity 
has been shown to be a risk factor for lymphoma, drug safety studies in RA with lymphoma 
as the outcome might be particularly susceptible to channeling bias.  
For bDMARDs other than TNFi, considerably less is known about the risk of cancer. These 
agents target different pathways in the immune system which could theoretically lower host 
surveillance against incipient tumors, or accelerate tumor progression. Abatacept is a CTLA-
4 fusion protein which inhibits the co-stimulatory signal from antigen-presenting cells (78). A 
pharmaceutical agent with essentially the opposite mechanism i.e. a CTLA-4 blocker, 
ipilimumab, is approved for the treatment of malignant melanoma (79), a fact which could 
prompt some concerns about the safety of abatacept in terms of risk of melanoma. 
Nevertheless, pooled data from RCTs (including open-label extensions) have not shown any 
increased risk of cancer among RA patients treated with rituximab, abatacept, or tocilizumab. 
(80-82).  However, RCTs are often small, more suited to studying short-term risks, and often 
use narrow inclusion criteria which excludes large groups of patients, e.g. patients with 
comorbid conditions such as a previous cancer. Therefore, observational studies should be 
more suited to studying the medium to long term risk of cancer with bDMARD therapy. On 
the other hand, observational studies have inherent limitations as well. Confounding and 
channeling bias is an obvious issue, especially since bDMARD therapy is often reserved for 
patients with more severe disease, patients that have failed other therapies, or patients with 
various comorbid conditions. Prior to the studies in this thesis, only a few observational 
studies had been published on the subject of non-TNFi bDMARDs and cancer, with mostly 
reassuring results (48, 83, 84).  
In Sweden, patients with RA are recommended to adhere to the national screening guidelines 
for cancer. A cancer in the medical history before treatment initiation, or the detection of a 
new tumour during ongoing treatment, may impact the choice of treatment in RA. For 
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example, The American College of Rheumatology recommends choosing a csDMARD over 
bDMARD in patients with a history of skin cancer (both melanoma and non-melanoma), and 
not choosing TNFi in patients with a history of a lymphoproliferative malignancy (85). 
Indeed, real-world data have shown that relatively few patients with a recent history of cancer 
receive treatment with TNFi (86). Channeling of patients with cancer in the medical history 
away from TNFi therapy highlights the clinical relevance of risk for cancer recurrence with 
TNFi. Previous observational studies on head and neck cancer (87), breast cancer (88), and 
overall cancer (89-92), have not shown an increased risk of cancer recurrence with TNFi 
therapy. However, these cancer recurrence studies are often low powered and, as previously 
stated, subject to channeling bias.  
1.8 CERVICAL CANCER 
Worldwide, cervical cancer is the fourth most common cancer in women affecting more than 
500,000 women per year (93). With a few rare exceptions, invasive cervical cancer is caused 
by persistent HPV infection, via low-, and high-grade dysplasia (94). Most often cervical 
cancer develops from squamous cell epithelia, but 10-20% are derived from glandular 
epithelia (95). Both premalignant squamous and glandular cells can be graded according to 
their malignant potential. In this thesis I will use the term low-grade dysplasia (LSIL) for 
mild dysplasia of either squamous or glandular origin (including cervical interaepithelial 
neoplasia grade 1, and atypical glandular cells), and high-grade dysplasia (HSIL) for 
moderate or severe dysplasia of either squamous or glandular origin (including 
adenocarcinoma in situ, cervical carcinoma in situ, cervical interaepithelial neoplasia grade 2 
and 3). Although most sexually active women will be infected by HPV at some point in their 
lives, only a fraction of infections become persistent, and even fewer develop invasive 
cancer. The aim of cervical screening program is to detect pre-cancerous lesions before they 
develop into invasive cervical cancer, and also to detect invasive cervical cancers at an earlier 
clinical stage. Cervical screening traditionally involves a Papanicolaou smear test, or “pap 
smear”, named after the Greek doctor that invented it in the early 20th century. Cells around 
the transformation zone of the cervix are sampled and examined under a microscope. If 
abnormal cells are detected, a subsequent colposcopy can be performed. Colposcopy 
visualizes the cervix and allows for biopsies to be taken for further histopathological 
examination. Since it was discovered that HPV causes cervical cancer, HPV testing has been 
introduced as an alternative, and a complement, to pap smear testing. The Swedish cervical 
screening program invites all women resident in Sweden to be screened every three years 
between the ages of 23-50, and every five years between the ages of 50-64 (previously 50-
60). Apart from pre-planned screening conducted within the framework of the national 
screening program, a substantial proportion of cervical screening results from opportunistic 
screening. Opportunistic screening is screening carried out, typically by a midwife or a 
gynecologist, during a regular check-up, or because of alarming symptoms such as vaginal 
bleeding. Organized, pre-planned screening, is considered more effective than opportunistic 
screening. Higher coverage is achieved when women are invited instead of taking the 
initiative themselves. Also, pre-planned screening can optimize the timing between the tests, 
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in terms of both protection and cost-effectiveness. Since the introduction of organized 
cervical screening in the 1960s, there has been a dramatic decrease in the incidence of 
cervical cancer (96). At the same time the incidence of cervical carcinoma in situ has 
increased due to earlier detection. Further decreases in the incidence of cervical cancer are 
expected with the introduction of HPV vaccines on the Swedish market in 2006, and an 
organized vaccination program of Swedish girls in 2012.  
 
Figure 1.3. Illustration of the progression from initial HPV-infection to invasive cervical cancer. ©The 
Nobel Committee for Physiology or Medicine 2008, Illustration: Annika Röhl 
Chronic inflammation and immunosuppression might impede host clearance of HPV 
infection, and thus increase the risk of cervical cancer. Therefore, the question if there is an 
increased risk of cervical cancer, either due to the disease itself or the associated treatments, 
has attracted interest in both RA and SLE. An observational study based on American 
healthcare claims databases found a 50% increased risk of high-grade dysplasia (CIN 2–3 or 
invasive cervical cancer) among bDMARD-naive women with RA compared to the general 
population (97). However, a large study based on the Californian Cancer Registry found a 
significantly decreased risk of cervical cancer among patients with RA compared to the 
general population (98). A meta-analysis by Simon et al. included 15 studies and found a 
pooled standardized incidence ratio of 0.87 (0.72, 1.05) compared to the general population. 
Thus there does not seem to be an increased risk of cervical cancer with RA per se (14). 
An observational study with data from the Danish Biologics Registry (DANBIO) did not find 
any difference in risk for cervical cancer comparing arthritis patients that were bDMARD-
treated with bDMARD-naïve (99). Two studies have been published on the risk of genital 
cancer among TNFi-treated women with RA with a history of cervical carcinoma in situ 
(100), and any premalignant lesion of the cervix (101). Although there were no events in the 
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TNFi-treated patients in either of the two studies, the number of patients included were too 
few (n=190 and n=233) to draw any firm conclusions. 
Several studies have found an increased risk of HSIL among patients with SLE (97, 102). 
However, for invasive cervical cancer the picture remains unclear. Several studies have 
shown no significant risk increase in SLE (103, 104). A collaborative effort resulted in a 
multi-center study that found no increased risk (SIR 1.27 95%CI 0.78-1.93)(18). On the other 
hand, a large register-based study from California reported a lower risk among women with 
SLE compared to the general population (105). Of note, the same study reported higher rates 
of cancer of the vagina or vulva, which are also HPV-associated, among women with SLE.  
Most of the studies on either SLE, or RA, and cervical cancer have not been able to consider 
important risk determinants, most importantly cervical screening. Whether women with SLE 
are appropriately screened for cervical cancer or not is not clear. On the one hand, patients 
who are already diagnosed with a severe chronic disease might be less inclined to screen for 
another disease. On the other hand, these patients are regular consumers of health care and 
might be reminded or referred to cervical screening in their regular contact with doctors and 
other health care professionals. Previous reports on SLE and cervical screening have found 
conflicting results, with both lower, and similar, rates of screening compared to the general 
population having been reported (103, 106). For RA, the degree of screening participation is 
also unclear, with both similar participation compared with the general population (103, 107), 
and suboptimal screening participation (108, 109), having been reported. 
A multicenter study published in 2004 found that treatment with immunosuppressants among 
women with SLE was associated with subsequent abnormal Pap smears (110). Although the 
results were adjusted for important risk factors, disease activity was not included. A higher 
risk of dysplasia or cervical cancer among women with SLE might be due to either the 
disease itself or the potent immunosuppressants that are used to treat the disease. A potential 
risk increase associated with disease activity or disease severity would be hard to disentangle 
from different drug exposures.  
1.9 BREAST CANCER 
Breast cancer is the most common invasive cancer in women, both in Sweden and 
worldwide. Although it also occurs in men, the incidence is more than 100 times higher in 
women (35). Established risk factors for breast cancer include advancing age, early age at 
menarche, old age at menopause, HRT, exposure for ionizing radiation, family history of 
breast cancer, BRCA1 or BRCA2 mutations, alcohol, and high BMI, as well as protective 
effects of parity, breast feeding, and physical activity (111). Mammographic screening was 
introduced gradually in Sweden between 1974 and 1997 (112). The rationale for 
mammographic screening is that the mortality of breast cancer can be lowered by 16-25% by 
the earlier detection (113, 114), though this is still somewhat controversial (115). The current 
national screening program invites women between the ages of 40-74 to be screened every 
18-24 months, and about 80% of invited women participate.   
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In the 1990’s, observational studies published from Sweden and Denmark showed a lower 
risk of breast cancer among women with RA (44, 45). This finding was repeated in some later 
studies (42, 71), while others found no such association (49, 116). A meta-analysis of 
observational studies by Smitten et al. from 2008 (37), showed a 15% decreased risk of breast 
cancer in women with RA. The paper included studies from Denmark, Sweden, Japan, 
Canada, the UK, Spain, and the USA, and cohorts of both bDMARD-treated, and bDMARD-
naïve patients. However, in the updated analysis by Simon et al. (117), 8 more recently 
conducted studies were added, and although the point estimate was very similar, there was no 
longer a statistically significantly decreased risk. Besides methodological differences, the 
study periods stretched from the 1960’s to the 2000’s, and therefore includes both women 
who were subject to mammographic screening and women who were not. Also the 
background risk of breast cancer in the populations varies by more than a factor of 5 between 
low risk countries such as Japan, and high risk countries such as the USA. A meta-analysis of 
cohort studies that was published in 2014 did not find a decreased risk of breast cancer in RA 
overall, but a decreased risk among women with RA in studies conducted on women in 
western countries, 0.82 (0.73, 0.93)(118). In studies conducted on women in Asia, instead an 
increased risk was reported 1.21 (95% CI 1.19-1.23). The authors point out that differences in 
breast density, an important risk factor for breast cancer, between different ethnic groups 
have been observed. However, a large Taiwanese study by Chen et. al included in both the 
meta-analysis by Simon et. al (46), and by Tian et. al (118), was heavily criticized by another 
Taiwanese study using the same data, for supposedly having miscalculated the SIRs (119, 
120). Chen et. al is the only study that has reported an increased risk of breast cancer in RA, 
SIR=1.21 (95%CI 1.19–1.23), while the study by Huang et. al found an SIR of 0.90 (95%CI 
0.78-1.03), more in line with previous studies.  
A reduced risk of breast cancer among women with RA might be explained by the presence 
of shared risk determinants. Interestingly, a study by Hellgren et al. noted a lower prevalence 
of breast cancer even before RA diagnosis, indicating that this might be the case (121). 
However, it is unclear what these risk determinants might be. It has been hypothesized that 
this potentially negative association between breast cancer and RA is due to hormonal 
changes in RA (122). The incidence of RA in women during the reproductive years is more 
than twofold that of men, after which the differences between the sexes is attenuated (4). 
Also, women with RA often experience amelioration or remission during pregnancy, and a 
flare-up after delivery is common (123, 124). Most of the hormonal risk factors for breast 
cancer are not known as risk factors for RA. For example, among 28,000 women in the 
women’s health initiative RCT, HRT was associated with an increased risk of breast cancer 
(125), but was not associated with developing RA (126). Likewise, parity is associated with a 
decreased long-term risk of breast cancer (127), but does not seem to be associated with the 
development of RA in general (128-130), although an increased risk of ACPA-negative RA 
has been reported in women of reproductive age (131). Long-term breast feeding seems to 
lower the risk of developing both RA (129, 130), and breast cancer (132). Current or recent 
use of oral contraceptives is thought to slightly increase the risk of breast cancer (133), 
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although it is probably dependent on the formula. Most studies investigating the relationship 
between use of oral contraceptives and development of RA have been unable to find an 
association (129, 130), although some have shown a protective effect (134, 135). However, 
early menopause, which is negatively associated with breast cancer (136), has been reported 
as a risk factor for RA, and in particular seronegative RA (130, 137, 138). Thus the 
relationship between hormones, breast cancer and RA does not seem straight-forward.  
Another hypothesis is that the lower incidence of breast cancer among RA patients is due to a 
protective effect of aspirin against breast cancer (139). A modest risk decrease has been 
consistently observed in case-control and cohort studies (140), although a large RCT 
comparing low dose aspirin (and vitamin E) every other day vs. placebo showed no 
difference in risk of breast cancer with aspirin use (141). Lastly, the observed differences in 
risk might be due to protective effects of RA therapy, or differences in detection rather than 
true differences. Because breast cancer is detectable through physical examination and 
screening, and RA patients are high-utilizers of healthcare they may be more inclined to 
attend mammographic screening. A cohort study based on US commercial insurance data 
found higher rates of mammographic screening among women with RA compared to non-RA 
controls (107), although it is not self-evident that this finding is generalizable to countries 
with organized national mammography program. 
Table 1.2. Relationship between hormonal risk factors and the risk of developing breast 
cancer, and RA, respectively. 
Risk factor Breast cancer RA 
Early age at menarche ↑ ↓? 
Late age at menopause ↑ ↓ 
Late age at first childbirth ↑ ? 
High parity ↓ ? 
Breast-feeding  ↓ ↓ 
HRT ↑ × 
Oral contraceptives ↑ × 
(↑=increased risk, ↓=decreased risk, x=no association, ?=inconclusive) 
About 85% of malignant breast tumors are estrogen and/or progesterone receptor positive. 
Through these receptors, the tumor can bind circulating estrogen from the blood stream, 
which stimulates growth. To counter this, pharmaceutical agents which block the effect of 
estrogen on breast tissue, are used. The main agents are Tamoxifen, which is an estrogen 
receptor modulator, and aromatase inhibitors (AI), which inhibit the production of estrogen. 
Arthralgia is a very common side effect of AI, and to a lesser extent also of tamoxifen. This 
has led researchers to investigate whether AI and tamoxifen increases the risk of not just 
arthralgia, but also of arthritis. Apart from case-reports (142), there are two observational 
studies published examining the risk of RA following AI and tamoxifen treatment in women 
with breast cancer (143, 144). These studies have shown that both tamoxifen and AI increase 
the risk of developing RA. However, they have not been able to consider some potentially 
important confounders, and they both lacked a proper comparator for the rate of RA.  
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2 OBJECTIVES  
2.1 OVERALL OBJECTIVES 
The overarching aim of this thesis was to better understand the association between chronic 
systemic inflammation, its treatments, and risk of cancer occurrence. 
2.2 SPECIFIC AIMS 
The specific aims of these this thesis were these: 
i) To examine screening patterns and the risk of cervical neoplasia in women with 
RA treated or not with TNFi. 
ii) To examine the risk of cervical neoplasia in women with SLE, overall and with 
respect to treatment, compared with women from the general population. 
iii) To assess the risk of incident malignant neoplasms in patients with RA treated 
with different bDMARDs. 
iv) To examine the relationship between RA and breast cancer, and how it is 
affected by anti-hormonal therapy for breast cancer. 
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3 METHODS 
3.1.1 Case-control study design 
A case-control study is a study in which the study population is sampled on the basis of the 
outcome, and then previous exposures of interest are compared. Commonly all subjects with 
an outcome (the cases), but only a subset of all potential controls are sampled. The controls 
should be sampled from the source population i.e. the same population that gave rise to the 
cases, and independent of exposure. The level of evidence of a case-control study is often 
described as lower than that of a cohort study. This is derived from the fact that the sampling 
of controls can create strong biases, and that if exposure is measured long after it has 
occurred e.g. in an interview with the subject at disease debut, it would make the study prone 
to recall bias. Recall bias occurs when cases remember their exposure more (or less) correctly 
than do controls. A classic example of this is in a study of malformations where mothers that 
have recently given birth to a baby with a malformation, and mothers that have given birth to 
a healthy baby, are interviewed about specific exposures during the pregnancy. The mothers 
that have given birth to a baby with malformations are thought to have gone through all 
aspects of the pregnancy, during the time that has elapsed between the birth and the 
interview, looking for a reason for the malformation. Therefore, they are more prone to report 
exposures resulting in differential misclassification and bias (145). In a case-control study 
that is conducted using prospectively collected data on exposures, this phenomenon will not 
occur. The function of the control subjects in a case-control study is to reflect the exposure 
distribution in the source population that gave rise to the cases. Finding appropriate controls 
in case-control studies can pose a major obstacle if it is hard to define the source population 
that gave rise to the cases. Think of a case-control study carried out in a hospital, where all 
cases of a certain disease during a specific period of time are gathered. The controls should 
then be sampled from the population that would have been admitted to that hospital, had they 
gotten the disease. The exact catchment area of a hospital can be hard to pin down, and even 
if you sample controls from the population of the exact geographical area, they might have 
been less inclined to seek care than the cases were. If you instead sample controls from 
patients who have been admitted to the same hospital for a different disease, the exposure 
may be linked to that disease, or to healthcare seeking behavior. In the case-control study that 
we conducted in this thesis, Study IV, controls were sampled from the entire Swedish 
population using incidence density based sampling, which should minimize this sort of bias. 
Incidence density based sampling means that for each new case, controls are sampled from 
disease-free individuals still at risk at the point in time that the case occurred. 
3.1.2 Cohort study design 
A cohort study is an intuitive design, in which the study population is sampled on the basis of 
an exposure, and then followed over a period of time, during which an outcome of interest is 
recorded. The occurrence of the outcome among the exposed and the unexposed is then 
compared, typically by calculating an incidence rate. The design is similar to that of an RCT, 
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with the big difference being that treatment is not randomly assigned, which opens up for 
bias. A more structured data collection process, and blinding, i.e. that the study participant 
and/or the researcher do not know which exposure has been allocated, are other important 
advantages that RCTs often, but not always, have over observational studies. Nevertheless, 
there are several advantages of cohort studies, e.g. they can potentially include huge study 
populations, and follow them over a long period of time which increases power and 
generalizability. Also, contrary to a case-control design, they can study several outcomes in 
tandem. They are often described as less cost-effective than a case-control study, because in 
order to study rare outcomes, data must be collected on a large group of subjects, most of 
which will never develop the outcome. However, this argument does not hold when utilizing 
registers with data already collected. In this thesis we used a cohort study design in all four 
studies.  
3.1.3 Survival analysis 
Survival analysis is a way of estimating the risk of an event by quantifying the time until the 
occurrence of said event. As the name implies, the event can be death, but these methods can 
be used to study time until any event of interest (cancer, bankruptcy, lottery win, 
imprisonment). Perhaps a more intuitive approach would be to compare the proportion of 
events occurring in the different exposure groups at the end of a study. However, such an 
approach would not be able to handle inter-individual variations in the person-time 
contributed. In survival analysis, the subjects can contribute information to the analysis even 
if information about their survival time is incomplete. If this is the case, the subject 
contributes information up until the time that they are removed from the risk set, which is 
called censoring. Censoring occurs for example if the person dies, drops out, is lost to follow 
up, or if the study ends. In most applications of survival analysis, it is important that the 
censoring is uninformative, i.e. that it is unrelated to the outcome of the study.  
Cox proportional hazards model, or Cox regression, is a method in survival analysis that 
allows for assessing the effect of several variables upon the time it takes for an event to occur. 
The variables need not be constant but can change over time. The Cox model assumes that 
the effect of a variable on the hazard is multiplicative. In Cox regression, the baseline hazard 
is unknown but considered equal for all individuals. As Cox regression is a time to event 
analysis, the time-scale must be defined. Different time-scales can be chosen depending on 
what is most appropriate for the study, such as calendar time, follow-up time, or attained age. 
In our studies we have used both follow-up time and attained age, depending on the study 
question. If two groups are compared to each other in a clinical study that assesses the 
outcomes of two drugs, then follow-up time since start of therapy might be the most 
appropriate time-scale. If instead we want to study the risk of death in women compared to 
men, then attained age might be the best fit for our model. Additional time-scales can be 
accounted for in the model. The Cox model assumes that hazards are proportional over time 
for all included variables. The assumption that hazards are proportional over time does not 
always hold, and should be tested. There are different ways of assessing if hazards are 
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proportional over time i.e. visual inspection of the cumulative hazard plots, stratifying the 
analysis on the time-scale used, or by introducing an interaction term between the 
independent variable and time. 
3.1.4 Selection bias 
Selection bias is a situation where a non-causal exposure-outcome relationship has been 
introduced in the study population that was not present in the source population, due to how 
the study population was selected or followed up. This means that we are conditioning on a 
common consequence of the disease and the exposure, as shown in Figure 3.1, where there is 
no direct link between exposure (E), and disease (D), but both cause C, which we are 
conditioning on (as denoted by the box around C). There are many different situations where 
this can arise, an intuitive example is the potential bias from studies that included volunteers, 
where subjects that are at a higher risk (e.g. because of a family history of the disease) might 
be more, or less, willing to participate. In the context of this thesis, selection bias could arise 
if the risk of cancer associated with bDMARDs differed between those included in ARTIS, 
and those that were not.  
 
Figure 3.1. Graphical depiction of selection bias. A spurious association between Exposure (E) and 
disease (D) is introduced by conditioning on a common effect (C). 
3.1.5 Confounding 
Confounding is a key concept in epidemiology which can bias the estimated effect of the 
exposure on the outcome. A confounder is a factor that is associated with both the exposure 
and the outcome, but is not on the casual path between them, or a common effect of them. 
Another way of describing it is as an open backdoor path between the exposure and the 
outcome, or a common cause of the exposure and the outcome. Figure 3.2 shows that there is 
no direct link between exposure E, and disease D, but both are caused by C, which will 
produce a spurious association between them, if not accounted for. Confounding can bias the 
result towards, or away from, the null, and the strength of this bias depends on the strength of 
the association between the confounder and both exposure and the outcome, as well as the 
prevalence of the confounder in the population. This means that also an observed null result 
can be due to confounding, hiding the true effect. Provided that good data are utilized, with 
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high specificity and sensitivity, it’s not hard to handle confounding in a study. Indeed, there 
are many available methods, such as adjusting in the model, matching, stratification, 
restriction etc. However, if there is misclassification or missing data, dealing with 
confounding will be harder, although there are also methods to alleviate this problem (e.g. 
imputation, quantitative bias analysis). Bias that arises from unknown confounders are 
perhaps an even larger threat to the validity a study, and there is no way to ascertain that this 
is not present. An excellent way of dealing with confounding, is by randomizing the exposure 
among the participants in the study population. Provided that the study population is large 
enough, this should result in an even distribution of the confounding factors, both known and 
unknown.  
 
Figure 3.2. Graphical depiction of confounding. A non-causal association between exposure (E) and 
disease (D) will be the effect of not accounting for the common cause (C). 
A certain type of confounding, called confounding by indication, or channeling, can 
constitute a major source of bias in observational drug effectiveness or drug safety studies. 
This arises from the fact the doctors don't randomize patients to different therapies. Instead, 
they use their clinical expertise, clinical guidelines, past experiences etc. to decide which 
treatment is the most appropriate for a given patient in a given situation. Perceived, or actual, 
risks that are associated with specific drugs affect the clinical decision making. In the context 
of this thesis, this is clearly seen in the low prevalence of previous cancer in TNFi-treated, 
and the high prevalence of previous cancers in rituximab-treated. This is not unexpected in 
light of the fact that some treatment guidelines have recommended rituximab, instead of 
TNFi, in patients with a history of prior malignancy, at least within the first 5 years (146). A 
variable that is recorded in the data, such as a previous malignancy, can be accounted for in 
the analysis, e.g. by restricting the analysis to patients with no history of a prior malignancy. 
However, if a specific therapy is avoided because of subtler reasons, such as a perceived 
higher risk of a malignancy for the patient, this can constitute a bigger problem. Also, as seen 
in Study III, most patients treated with other bDMARDs had previously been treated with 
TNFi, and failed. Non-random allocation of treatment is the most important difference 
between observational studies and RCTs. Actual, or perceived, differences in safety or 
effectiveness can cause channeling towards, or away from, drugs. Furthermore, the clinician’s 
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treatment decision can be influenced by such factors as, e.g. the cost of the drug, or personal 
preferences of either the doctor, or the patient. Differences in healthcare organization, drug 
reimbursement schemes, guidelines and clinical traditions, can further influence channeling 
and hamper cross-country study comparisons. Whether there is a clear scientific rationale, or 
not, behind the channeling, it should be addressed in the study design. A recent paper by 
Frisell et al. tried to map out the patient characteristics of Swedish RA patients initiating 
bDMARD therapy, and to also predict how these characteristics influenced the risk of 
outcomes such as malignancy (147). They found that most, but not all, of the difference in 
predicted risk of malignancies disappeared when age and sex was adjusted for, but that 
medical history and disease activity also need to be accounted for. In the context of this 
thesis, confounding by indication was an important issue in Studies I-III. Table 1 in Study 
III shows substantial differences between the drug cohorts in terms of e.g. age, sex, 
education, and medical history (including a previous malignancy). 
3.1.6 Measurement error 
Measurement error means that the assigned value of a variable differs from the actual value, 
and is a ubiquitous source of bias in medical studies. First of all, the variable that we have 
recorded is often not exactly the same as what we are actually interested in, but a proxy. 
Secondly, it is unlikely that all values are recorded with exact precision. We are concerned 
with three types of measurement error, that of exposure, outcome, and of confounders. 
Measurement error can cause differential, or non-differential, misclassification. Non-
differential misclassification means that it is independent of other variables in the analysis. 
Non-differential misclassification of exposure or outcome is often considered less grave than 
differential, because it will generally bias the estimate towards the null. Differential 
misclassification means that it is not independent of other variables in the analysis, and can 
cause bias away from, as well as towards, the null.  
In this thesis the outcome is generally cancer, captured through the Cancer Register which 
has excellent coverage and validity (148). However, the time between inception of cancer to 
detection can vary greatly, and might be dependent on such factors as screening, frequency of 
doctors’ visits, degree of symptoms etc. Although we can be fairly certain that a subject that 
has been diagnosed with cancer is a true case, we have no way of ascertaining that a subject is 
disease free at a given point in time. If, however, cancer detection is dependent on the 
exposure, then we potentially have an even greater problem, because this will produce a 
biased estimate of the relative risk between exposed and unexposed. Let’s say that our 
exposure is TNFi, and our outcome is lung cancer. If initiators of methotrexate or TNFi 
undergo a routine chest x-ray which can potentially detect an underlying lung cancer, and our 
comparator group doesn’t, this can cause differential misclassification of disease.  
As for misclassification of exposure, we know that a prescribed drug has been dispensed, but 
usually we have no way of knowing if the patient has actually taken the drug. Sometimes we 
have a problem with over-the-counter drugs that haven’t been recorded in our registers. 
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Furthermore, exposure status is often dichotomized which necessitates a cut-off, even though 
actual exposure might not be so clear cut.  
 
Figure 3.3. Incident RA patients 2006-2010 with ICD-codes for other rheumatic diseases 
(AS=ankylosing spondylitis, PSA=psoriatic arthritis, SPA=other spondyloarhropathy, or SLE) in the 
NPR, before and after RA diagnosis, and by clinic. 
Rheumatic diseases can present in different ways and what might be an obvious diagnosis at 
a later point in time might be unclear in the beginning. In this thesis we have used algorithms 
to identify patients in the patient register based on the type of diagnosis, the number of 
diagnoses, and where it has been made, but this inevitably leads to a trade-off between 
sensitivity and specificity, as well as latency period between actual disease onset and start of 
follow-up. In Figure 3.3 we see that if we pick a random patient from the NPR with a first 
RA diagnosis during 2006-2010, there is a 15% chance of that patient having at least one 
International classification of diseases (ICD) code in the NPR, with a diagnosis of some other 
rheumatic conditions (ankylosing spondylitis, psoriatic arthritis, other spondyloarhropathy, or 
SLE) during either the preceding 5 years, or the coming 5 years. We see also that if this 
diagnosis was made at an internal medicine or rheumatology clinic, the chance is instead 9%. 
This highlights the importance of proper algorithms being used when adopting a register-
based approach for identifying disease.  
The algorithm for identifying SLE in the patient register has been reported as highly accurate 
(positive predictive value of 98%), when validated against clinically confirmed cases (149). 
The positive predictive value of a similar RA algorithm to the one we used in Studies I and 
III, has been reported as 90%, when validated against the 1987-, and 2010, ACR-criteria (12, 
150, 151). In Study IV, we used the same definition, but also included cases of RA in the 
Swedish Rheumatology Quality Register (SRQ). Although no guarantee of accuracy, these 
diagnoses have been assigned by a rheumatologist. 
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3.1.7 Immortal time bias 
Immortal time bias arises when person-time, during which a subject is not at risk for the event 
is counted in the analysis (145). For example, if the outcome is death, and we require a 
subject to have two diagnoses of RA to be included, person-time before the date of the second 
diagnosis should be excluded from the analysis because we have conditioned on the subject 
being alive up until this point. If we include this time, and compare the survival rates in RA 
with control subjects that have no such requirement, we will inflate the denominator of RA 
person-time and overestimate their survival. Although the name “immortal time” implies that 
death is the outcome, this bias can arise whenever person-time when a subject is not at risk 
for the event is included, regardless of the outcome. To avoid this error in this thesis, time 
before all the inclusion have been met has been excluded, or if subjects have been allowed to 
switch treatment groups, time has been allotted to the appropriate exposure group. 
3.1.8 Reverse causation 
Reverse causation, refers to a situation where A does not cause B, rather B causes A. Cross-
sectional studies, where exposure and outcome are measured at the same point in time, are 
especially susceptible to this type of bias. In this thesis we used prospectively collected data, 
which should minimize the risk of this happening. However, it is sometimes hard to 
determine at which point in time an event occurs. The debut of both rheumatic disease, and 
cancer can often be insidious, and disease processes will often have started long before it is 
diagnosed. Even worse, initiating a new treatment might unmask underlying occult disease, 
such as malignancy. Also, sometimes malignancies present with symptoms that can mimic 
that of other diseases, including rheumatic disease, so called paraneoplastic phenomena 
(152). This can result in a subsequent false diagnosis of, e.g. RA, instead of the undiscovered 
tumor. Reverse causation can be addressed by using a wash-out period, i.e. excluding the 
time immediately following exposure from the analysis. Other options include performing 
sensitivity analyses to test the robustness of the findings by moving the index date back and 
forth, or analyzing the risk stratified by time since start of follow-up. 
To address this issue in Studies I and III, we performed secondary analyses stratified by 
time since start of follow-up. The result of these analyses in Study I seemed to indicate a 
trend towards lower risk of cervical dysplasia outcomes, but not of invasive cervical cancer. 
This could be due to intensified screening associated with start of TNFi, chance finding, or 
depletion of susceptibles. In Study III, there was no clear trend for overall cancer risk when 
stratifying by time since start of TNFi. Due to the recent introduction of the other 
bDMARDs, and low power, theses analyses were not performed for other bDMARDs, or 
other outcomes. In Study III, we also performed a sensitivity analysis where a 90-day lag 
period was added between inclusion and start of follow-up, with similar results compared to 
the main analysis. 
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Figure 3.4. Graphical representation of accuracy and precision. A, good accuracy and precision. B, 
Good precision, bad accuracy. C, Bad accuracy and precision. D Good accuracy, bad precision. 
3.1.9 Random error 
Confounding, selection bias and measurement error all refer to systematic errors in studies, 
which are not affected by study size. Random error is the other type of error that can lead to 
discrepancies between the observed, and the true estimate. Random error decreases with 
increased study size, which is recognized by lower p-values and narrower CIs. Although 
important to consider, random error, or the precision of a study, is perhaps sometimes given 
too much attention. If strong biases in a well-powered study have not been dealt with, we will 
have a precise estimate of a biased result, such as in Figure 3.4 (B).  In this thesis we used a 
threshold of 0.05 for p-values, and calculated 95% CIs. 
3.1.10 External validity 
Internal validity refers to in which degree the results of a study is free from bias. External 
validity refers to the generalizability of the results of the study. If a study is conducted in only 
men, can we draw inference from that study when it comes to women as well? Whenever the 
study population is not representative of the target population, this issue might be raised. 
However, sometimes we do not want the study population to be representative of the target 
population. In a RCT, rigorous criteria are often applied, as to minimize the noise from 
factors other than that of the causal effect of the exposure on the outcome. Effect 
modification, i.e. the effect of X on Y, varies across strata of Z, might be present, but it’s not 
feasible to redo a study under all thinkable conditions, without a biological rationale. There 
are often trade-offs between internal validity, external validity, and precision. In such cases 
internal validity should be ranked very high, because if results are not valid, precision and 
generalizability are meaningless (145). 
In this thesis, we have used nationwide registers, with very high coverage of the Swedish RA 
and SLE populations, which should ensure high generalizability of the results to these 
respective populations. Nevertheless, there has been some underreporting to the NPR from 
some private practitioners, which could have led to misclassification of some patients. 
However, most patients are treated by hospital-based rheumatologists, and some of the 
missing patients in the NPR have been captured by the SRQ. Also, some patients with mild 
disease treated in primary care, or in remission, might also be missed.  
A B C D 
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3.2 DATA SOURCES 
This thesis contains four register-based studies conducted on Swedish patients with RA and 
SLE, respectively. Sweden has a long tradition of maintaining records on its citizens for 
economic and military purposes, dating back to the 16th century. The 20th century saw the 
development of many new registers, including healthcare and educational data. Since 1947, 
all Swedish residents are issued a personal identity number (PIN) which allows for linkage 
between registers (153). Using algorithms, patients with rheumatic disease can be identified 
from these registers. These data can then be enriched by information on treatment, 
comorbidities etc. from other registers, including quality of care registers. This allows for 
relevant comparisons by treatment and other characteristics within patient populations. 
Furthermore, by matching these individuals on certain parameters to individuals in the 
general population, e.g. cancer incidence can be benchmarked against the background risk in 
the population. Swedish healthcare is population based and tax funded and reporting to the 
healthcare registers is mandatory for clinicians. This ensures a high coverage and minimizes 
the risk of selection bias, thus providing a (near-) perfect setting for register-based medical 
studies.  
 
Figure 3.5. Timeline depicting the inception of Swedish registers utilized in this thesis  
3.2.1 The Swedish Rheumatology Quality Register 
The SRQ was started in the late 1990’s to follow patients with RA. Since then, it has 
expanded to include other rheumatic diagnoses. The register serves as an integrated support 
tool in clinical decision making. At each visit, the clinician enters data on disease activity, 
disability and treatment, which can thus be followed longitudinally. ARTIS is a subset of the 
SRQ for patients treated with bDMARDs. ARTIS has an estimated coverage of 95% of 
bDMARD treated patients in Sweden, and validation against the PDR indicate a high degree 
of coherence (154). This register was used to identify bDMARD treatments in Study I and 
III, and incident RA patients in Study IV. 
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Table 3.1. The main data sources that were used in the studies included in this thesis, and what 
information was used from them 
Data source  
 
Identification of subjects  Data used  
The Swedish Rheumatology 
Quality Register   
Patients with RA  Health assessment 
questionnaire, Disease activity 
score of 28 joints, treatment 
information (1999-)  
National Patient Register  Patients with main or 
contributory diagnosis for 
Rheumatoid arthritis and 
Systemic lupus erythematosus  
Health care use and 
comorbidities (not primary 
care; inpatient: 1971-; 
outpatient: 2001-)  
Cause of Death Register - Deaths (1956-)  
Prescribed Drug Register  -  Dispensed drug prescriptions 
(not in-hospital drug use; July 
2005 -)  
Cancer Register - Information on incident 
cancers (date, ICD-code, TNM-
stage, 1958-)  
Cervical Screening Registry - Cytology and histopathology 
testing 
Register of the Total 
Population  
Sampling of 
comparators/controls  
Birth, death, civil status, 
country of birth, migration 
(1968-)  
Longitudinal integrated 
database for health insurance 
and labor market studies 
-  Level of education (1990-). 
Sick-leave and disability 
pension (1994-) 
Multi-generation register - Children, family history of 
cancer (together with the 
cancer register) 
3.2.2 The National Patient Register 
The National Patient Register (NPR) is administered by the National Board of Health and 
Welfare and was founded in 1964. It contains data on every discharge from inpatient care 
since 1987, and since 2001 visits in non-primary outpatient care are also included. Each 
discharge or visit is ICD-coded, with clinic, date, and main- and contributory diagnoses 
specified (155). The NPR was used in Studies I-IV to identify RA and SLE patients, as well 
as comorbid conditions. 
3.2.3 The Swedish Cancer Register 
The Swedish Cancer Register was started in 1958 and is administered by the National Board 
of Health and welfare. Reporting of incident cancers is mandatory for all health care 
providers and the coverage is estimated at >95% (148). Both the clinician and the 
  25 
pathologist/cytologist report to the register. Apart from administrative data (PIN, hospital), 
medical data on site of tumor (ICD), basis (clinical or histopathological) and date of diagnosis 
are recorded in the regsiter. Also, since 2002, histological type is coded according to TNM 
Classification of Malignant Tumours (TNM) or The International Federation of Gynecology 
and Obstetrics classification. The Cancer Register was used in Studies I-IV to identify 
incident and previous cancers. 
3.2.4 The Prescribed Drug Register 
The Prescribed Drug Register (PDR) was set up in 2005 and gathers data on prescribed drugs 
in Sweden (156). Each dispensed drug is listed according to the Anatomical Therapeutic 
Chemical Classification System, along with dose, quantity, date, and customer PIN. It does 
not capture over the counter drugs. Hospital-administered drugs, including intravenous 
bDMARDs, are only partially captured (e.g. infliximab and rituximab). The PDR was used in 
Studies I-IV to identify dispensed prescriptions.  
3.2.5 The Total Population Register 
The Total Population Register started in 1968 and is administered by the Swedish Tax 
Agency. It contains data on all long-term Swedish residents. Each person is listed by PIN, 
sex, name, birth data (where and when), address, emi- and immigration, income and 
citizenship (157). The register also contains the Multi-generation register, through which data 
on parents, children, and siblings can be identified for Swedish residents 1961-, and people 
born in Sweden 1932 or later. Coverage is high for persons born in Sweden 1968 or later, but 
lower for immigrants, adopted children, and older cohorts. The register also includes the 
longitudinal integrated database for health insurance and labor market studies (LISA) which 
integrates existing data from the labour market, educational and social sectors. Information 
from the Total Population Register on education, birth, migration, education, sick-leave and 
disability pension as well as family history, was used in Studies I-IV of this thesis. 
3.2.6 The National Cervical Screening Registry 
Female residents in Sweden, aged 23-64, are invited to partake in cervical screening. The 
National Cervical Screening Registry (NKCx) gathers data on screening invites and all 
cervical screenings (and ensuing cytology and histology tests) in Sweden, both opportunistic 
and pre-planned. All laboratories have reported cytological results since 1997, and 
histological results since 1998 (158). The coverage for cervical cytology and histology tests 
has been estimated at >90%. In 2012, an estimated 64% of invited women (aged 23-60) had a 
cervical smear recorded within 1 year of the invitation. The same year, 69% of registered 
pap-smears were classified as pre-planned, as opposed to opportunistic. Data from the NKCx 
was used to identify screening appointments, and cytology/histopathology for premalignant 
lesions in Studies I-II. 
 26 
 
Figure 3.6. Illustration of register linkages. Patients are identified in SRQ/ARTIS and/or the Patient 
Register, and these data are enriched by linkages to registers with data on comorbidities, drug 
dispensings, socioeconomy and demography.  
 
Figure 3.7. Overlap between prevalent patients 2006-2016 registered as RA patients in SRQ, and 
identified in the Patient Register using an algorithm with a requirement of at least 2 visits, 1 of which 
had to have been at a Rheumatology or Internal Medicine clinic. 
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3.3 ETHICAL CONSIDERATIONS 
The studies presented in this thesis are all register-based studies. All subjects are anonymized. 
Data are only kept on secure servers with restricted access. The Regional Ethical Review 
Board in Stockholm has reviewed and approved these studies.  
A lack of informed consent is problematic and at least seemingly at odds with Helsinki 
declaration. However, according to Swedish law, research may be carried out without 
informed consent if it can be assumed that it may provide knowledge unattainable elsewise, 
and it may be of direct benefit to the subject or patients with the same condition, provided 
that it does not cause significant harm to the study subject. The study must be reviewed in 
advance by an ethical review board.  
The studies presented in this thesis deal with cancer as a comorbid condition to rheumatic 
disease. These conditions cause physical and mental harm to patients and their families, and 
are often fatal. The studies we are conducting can hopefully contribute knowledge to the field 
and are of direct clinical relevance. An increased understanding of the risks facing these 
patients may help us tailor their treatments properly so as to alleviate, or even preempt 
disease. Our belief, and our hope, is that the benefits of having conducted these studies 
outweigh the potential harm caused by them. 
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4 STUDY DESIGN AND RESULTS 
4.1 OVERVIEW 
All four studies were completely register-based. Different registers were linked together to 
identify the study populations and data on their exposures, outcomes, and potential 
confounders. Also, all four studies were cohort studies, although in Study IV a case-control 
design was also adopted. All studies were performed using SAS statistical software (version 
9.4; SAS Institute Inc)  
In Study I and III, RA patients (incident or prevalent) and their respective bDMARD 
therapies were identified through ARTIS. Thus we chose to rely on the RA diagnosis in 
ARTIS, and did not incorporate information from the NPR. In both of these studies biologics-
naïve comparator cohorts were set up. Although the SRQ contains a substantial proportion of 
biologics-naïve RA patients in Sweden, coverage is not complete and causes related to 
inclusion in the SRQ could bias the relationship between RA and adverse outcomes, 
including cancer. Therefore, when setting up biologics-naïve RA comparator cohorts we used 
algorithms to identify them in the outpatient subset of the NPR instead. We required two or 
more visits with an RA ICD-code as the main or contributory diagnosis. At least one visit had 
to have been at an internal medicine or rheumatology clinic. By linking these patients to the 
PDR, active comparator csDMARD-treated cohorts could be set up. In Study IV, new-onset 
RA patients were identified by combining information from the SRQ and the NPR. Patients 
were required to have either 1) two visits in the outpatient subset of the NPR with an RA 
diagnosis (main or contributory), and at least one visit in a rheumatology or internal medicine 
clinic, or 2) an RA diagnosis in the SRQ. No more than 18-months were allowed to have 
passed between a first arthritis diagnosis, or the date of disease debut recorded in the SRQ, 
whichever occurred first, and fulfillment of the diagnosis defining criteria listed in 1) or 2). In 
Study II, SLE patients were identified through the NPR, using algorithms similar to those in 
Study I and III. We required two visits in either in- or outpatient care in the NPR, with an 
ICD-coded SLE diagnosis (excluding drug-induced Lupus). Also, at least one diagnosis had 
to have been from a department or specialist typically known to diagnose, treat or manage 
SLE (rheumatology, dermatology, nephrology, internal medicine and pediatrics). 
In all four studies, general population comparator cohorts were set up by linkage to the Total 
Population Register, matched 1:5, or 1:10, on vital status, sex, year of birth and place of 
residence.  
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Table 4.1. Overview of the four studies 
 Study I Study II Study III Study IV 
Short Title 
RA, TNFi and the 
risk of cervical 
neoplasia 
Cervical neoplasia in 
SLE 
Immunomodulators 
and Risk of 
Malignant 
Neoplasms 
Breast cancer and 
RA 
Design Cohort Cohort Cohort 
Cohort and Case-
control 
Disease RA SLE RA RA 
Comparison 
TNFi vs. csDMARD; 
csDMARD vs. 
General population 
SLE vs. general 
population; 
antimalarials vs. 
immuno-
suppressants 
TNFi, rituximab, 
abatacept, 
tocilizumab vs. 
csDMARD 
Incident RA vs. 
General population 
Data source Swedish registers Swedish registers Swedish registers Swedish registers 
Study 
period 
1999-2012 2006-2012 2006-2015 2006-2016 
Outcomes 
Cytology screening 
with normal 
outcome, LSIL, HSIL, 
invasive cervical 
cancer 
Overall cervical 
neoplasia, LSIL, 
HSIL, invasive 
cervical cancer 
Overall cancer, solid 
malignancy,  
hematologic 
malignancy, 
squamous cell skin 
cancer, melanoma 
Breast cancer in 
patients with RA, RA 
in patients with 
breast cancer, with 
or without anti-
hormonal 
treatment 
4.2 STUDY I 
Study I was a cohort study in which cervical screening and the risk of cervical neoplasia in 
women with RA was examined 1999-2012. 
Exposure 
We defined three exposure groups, 1) biologics-naïve women with RA starting a TNFi as the 
first ever biologic, 2) biologics-naive women with RA in general, 3) general population 
referents.  
1) In ARTIS, we identified all RA patients who initiated TNFi therapy as their first ever 
bDMARD. Start of follow-up was set to the date of TNFi therapy inititation. In the 
main analysis, a once exposed always exposed approach was adopted. 
2) In the outpatient subset of NPR, we identified all women with two or more visits with 
an RA ICD-code as the main or contributory diagnosis. At least one visit had to have 
been at an internal medicine or rheumatology clinic. Patients with a prior diagnosis of 
juvenile idiopathic arthritis, ankylosing spondylitits, SLE or psoriatric arthritis were 
excluded. Start of follow-up was defined as the first date when all the inclusion 
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criteria were fulfilled. Patients were censored at start of first bDMARD, and if that 
was a TNFi, they were allowed to switch cohorts to the TNFi cohort. 
3) By linking the biologics-naïve RA cohort to the Population Register, a general 
population comparator cohort was set up. For each RA patient, 10 randomly selected 
referents were identified, matched on year of birth, sex, and county of residence. Start 
of follow-up was set to that of their respective biologics-naïve patient with RA.  
Outcomes 
Four different outcomes were defined using data from the NKCx and the Cancer Register.  
1) A first cytology screening, either pre-planned or oppurtunistic, with a normal 
outcome during follow-up 
2) First LSIL in individuals with no prior cervical dysplasia or invasive cervical cancer, 
before (excluded). Subjects were censored on HSIL or invasive cervical cancer during 
follow-up. 
3) First HSIL during follow-up in individuals with no prior HSIL or invasive cervical 
cancer (excluded). Subjects were censored on invasive cervical cancer during follow-
up.  
4) First invasive cervical cancer during follow-up in individuals with no history of 
invasive cervical cancer at start of follow-up.  
Covariates and statistics 
End of follow-up was defined as first of 31 December 2012, death, emigration, a total 
hysterectomy, date of any solid organ transplantation and occurrence of the outcome under 
study. We computed the crude incidence, and performed Cox regression analyses. Covariates 
that were considered in our models were age, year of birth, educational level, marital status, 
previous screening, healthcare utilization and comorbidities. In a subset of the study 
population, we had access to data on parity and family history of cancer, and therefore the 
effect of these potential confounders were assessed separately. Attained age was used as the 
time-scale in Cox regression analyses, but alternative time-scales were also tested (follow-up 
time, calendar time).  
In addition to the main analysis, several sensitivity analyses were performed. In order to have 
an active comparator, and a more contemporary set of patients treated with TNFi, we 
restricted the study period to 2006-2012, and added a requirement of csDMARD treatment 
for the biologics naïve RA cohort. In the same sensitivity analysis, we also assessed the risk 
for new-users of TNFi 2006-2012. Also, the effect of two alternative exposure time-windows 
was tested instead of ever-since first exposure. On-drug in which TNFi-treated patients were 
censored after discontinuation of the specific TNFi-agent (+90 days), and on-class, in which 
TNFi-treated patients were kept in the risk set upon switching to another TNFi-agent, but 
censored on TNFi discontinuation (+90 days) (Figure 4.1). 
Main results of study I 
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We included 9629 TNFi initiators, 34,984 biologics-naive women with RA and 300,331 
general population comparators in our analyses. The TNFi cohort was younger, and had 
achieved a higher level of education, compared with the other cohorts. At baseline, a majority 
of TNFi initiators (71%) were treated with at least one concomitant csDMARD, and had a 
disease duration of 8.2 years. 
 
Figure 4.1. Representation of alternative exposure windows. Patients are considered bio-naïve until 
start of first bDMARD, at which point they switch cohorts. In Scenario A, we use an “ever exposed” 
approach when considering bDMARD treatment, event 1 is thus counted towards the csDMARD-
cohort, and events 2-3 are counted towards the bDMARD-cohort, even though event 3 occurred after 
bDMARD treatment cessation.  In scenario B, using an “on drug” approach when considering 
bDMARD treatment, event 3 is not counted in the analysis because it occurred after termination of 
treatment.  
Comparing biologics-naive RA with the matched general population comparators, we noted 
no differences in age-adjusted Cox regression for time to first screening with normal result, 
with a hazard ratio (HR) of 1.01 (95%CI 0.99-1.03) (Table 4.2). Cox regression adjusted for 
demographic factors, socioeconomic factors, previous screening and comorbidities, revealed 
a slightly higher HR for biologics-naïve RA, HR=1.08 (95%CI 1.06-1.10). The risk of both 
LSIL, and HSIL, was increased among biologics-naïve RA, with fully adjusted HRs of 1.53 
(1.23-1.89), and 1.39 (1.16-1.66), respectively. Both crude and adjusted rates of invasive 
cervical cancer were similar between biologics-naïve RA and the general population 
compators.  
In the TNFi cohort, the adjusted rate of cervical screening was similar to that of biologics-
naïve RA, HR=1.01 (95%CI 0.98-1.05) (Table 4.2). The risk of LSIL was not statistically 
significantly increased, HR=1.23 (95%CI 0.87-1.74). However, the fully adjusted rates of 
both HSIL, HR=1.36 (95%CI 1.01-1.82) and invasive cervical cancer HR=2.10 (95%CI 1.04-
4.23), were higher in TNFi initiators.  
For LSIL and HSIL, comparing TNFi initiators to biologs-naïve, there were no obvious 
differences in HR across follow-up (if anything a downward trend in HRs). For invasive 
cervical cancer, small numbers limited comparisons. 
Several sensitivity analyses were conducted in which we tried to map out the effect of 
different exposure definitions (“on drug” instead of “ever treated”), past cervical screening 
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history, family history of cervical cancer, parity et.c, with results which were mostly in 
accordance with the main analyses. Restriced to subjects with a normal cervical screening as 
the most recent result, there was a high risk of invasive cervical cancer among TNFi 
inititators compared to biologics-naïve RA (HR=3.77, 95%, CI 1.35-10.48). On the other 
hand, we found only one case of invasive cervical cancer during 18,000 person-years, in an 
analysis restricted to more recent initiators of TNFi (2006-2012).  
 
 
*= Stratified on decade of birth and adjusted for educational level, number of cervical screens past five 
years, co-morbidities, marital status and total days spent in hospital during last 5 yrs, also implicitly 
adjusted for age since age was used as the model’s time scale 
 
4.3 STUDY II 
Study II was a cohort study in which the risk of cervical neoplasia, overall and with respect 
to treatment, was examined 2006-2012, and compared to that of the general population. 
Exposure 
Female patients with SLE during 2001-2012 were identified in the NPR. By linking this 
cohort to the Total Population Register, a cohort of general population comparators, matched 
1:5 on sex, year of birth and, county of residence, was set up. Also two sub-cohorts of SLE 
patients were defined based on treatment with antimalarials or other immunosuppressants. 
The immunosuppressants cohort consisted of SLE patients with at least one filled prescription 
of mycophenolate mofetil, azathioprine, cyclophosphamide, ciclosporin, methotrexate, or 
rituximab. Person-time in this sub-cohort was classified as once exposed, always exposed. 
The antimalarials sub-cohort consisted of SLE patients who had filled at least one 
prescription of hydroxychloroquine or chloroquine phosphate. Patients in the antimalarials 
sub-cohort with previous exposure to immunosuppressants were excluded. Patients in the 
Table 4.2. Number of persons and events, crude incidence, and hazard ratios for the different cervical 
outcomes under study. 
Outcome 
definition 
Cohort Number 
of events 
Crude incidence 
per 100,000 pys  
Adjusted* HR Adjusted* HR 
First screening 
with normal 
result 
TNFi 4362 14 599 1.01 (0.98-1.05)  
Bio-naïve RA 10 958 9224 REF 1.08 (1.06-1.10) 
Gen pop 114 943 9556  REF 
LSIL TNFi 52 95 1.23 (0.87-1.74)  
Bio-naïve RA 99 57 REF 1.53 (1.23-1.89) 
Gen pop 852 45  REF 
HSIL TNFi 75 136 1.36 (1.01-1.82)  
Bio-naïve RA 137 79 REF 1.39 (1.16-1.66) 
Gen pop 1332 70  REF 
Invasive cervical 
cancer, overall 
TNFi 14 24 2.10 (1.04-4.23)  
Bio-naïve RA 25 14 REF 1.09 (0.71-1.65) 
Gen pop 275 14  REF 
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antimalarials sub-cohort were censored at first filling of an immunosuppressant prescription, 
with subsequent switching of sub-cohorts.  
 
Outcomes 
Outcomes were identified using data from both the NKCx and the Cancer Register. The main 
outcome was a composite outcome defined as a first LSIL, HSIL, or invasive cervical cancer. 
As secondary outcomes, the main outcome was split into three separate outcomes:  
1. A first ever LSIL, in women with no history of cervical dysplasia or invasive cervical 
cancer before start of follow-up, and no HSIL or invasive cervical cancer during 
follow-up.  
2. A first ever HSIL, in women with no history of HSIL or invasive cervical cancer 
before start of follow-up, and no invasive cervical cancer during follow-up 
3. A first ever invasive cervical cancer 
 
Covariates and statistics 
End of follow-up was defined as first of 31 December 2012, death, emigration, a total 
hysterectomy, date of any solid organ transplantation and occurrence of the outcome under 
study. In all analyses, the full SLE cohort was compared to the general population 
comparators, and the treatment-defined sub-cohorts were compared to each other. 
Participation in cervical screening was analyzed using t-tests and Cox regression. For the 
primary and secondary outcomes, we compared the crude incidence and performed Cox 
regression analysis with attained age as the time-scale, and adjusted for start year, level of 
education, healthcare utilization, number of children, marital status, family history of cervical 
cancer and prior cervical screening. Also, in head-to-head analyses of the two sub-cohorts, 
we adjusted for prior oral corticosteroids and oral contraceptives at baseline. To investigate 
effect modification by age and thus any non-proportionality over the time scale used, we 
plotted hazard functions, introduced an interaction term between the exposure and the time 
scale, and stratified analyses on three age bands (23-44, 45-64 and 65+ years old). 
Several sensitivity analyses were performed. To account for disease duration, we examined 
risks among women who were diagnosed with SLE for the first time in the NPR <2 years 
prior to the start of follow-up. Also, we analyzed models adjusted for use of oral 
corticosteroids during follow-up. Lastly, in another sensitivity analysis, patients with at least 
one dispensing of leflunomide, tacrolimus or sirolimus were also included in the 
immunosuppressants sub-cohort. 
Main results of study II 
The full SLE cohort consisted of 4976 women with SLE, of whom 1942 fulfilled the entry 
criteria for the antimalarials sub-cohort, and 2175 for the immunosuppressants sub-cohort 
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(including 473 subjects who switched cohorts and contributed person-time to both) (Table 
4.3). Median age at entry was 51 in the full SLE cohort, 49 in the antimalarials cohort, and 46 
in the immunosuppressants cohort. At entry, time since first SLE diagnosis in the outpatient 
register was shorter in the antimalarials cohort (median 2.5 years), than in the 
immunosuppressants cohort (median 3.7 years). Comorbidities were more frequent and 
healthcare utilization was higher in the immunosuppressants cohort, than in the antimalarials 
cohort. We noted numerical differences in cervical screening during follow up, but cox 
regression analyses of time to first screen, taking age and follow-up time into account, 
revealed no statistically significant differences across any of the SLE cohorts, or vs the 
general population. 
Table 4.3. Risk of cervical dysplasia and invasive cervical cancer among the cohorts of SLE patients 
and matched subjects. 
 
Number of 
patients at 
risk 
Number 
of events 
Total 
follow-up, 
years 
Crude 
incidence per 
100,000 
person-years 
Fully adjusted HR 
(95% CI)b 
Composite outcome of cervical dysplasia and cancer 
Full SLE 4550 121 23136 523 2.12 (1.65-2.71) 
General population 28113 336 155543 216 REF 
Immunosuppressantsa 1981 73 9002 811 1.83 (1.15-2.91) 
Antimalarialsa 1783 26 6564 396 REF 
First ever LSIL 
Full SLE  4550 53 23136 229 2.33 (1.58-3.44) 
General population 28113 115 155543 74 REF 
Immunosuppressantsa 1981 30 9002 333 2.33 (1.08-5.02) 
Antimalarialsa 1783 9 6564 137 REF 
First ever HSIL 
Full SLE  4619 75 23589 318 1.95 (1.43-2.65) 
General population 28299 232 156738 148 REF 
Immunosuppressantsa 2022 43 9229 466 1.44 (0.82-2.54) 
Antimalarialsa 1812 19 6687 284 REF 
First ever Invasive cervical cancer 
Full SLE  4976 5 25666 19 1.64 (0.54-5.02) 
General population 29703 17 165412 10 REF 
Immunosuppressantsa 2175 5 10011 50 NA c 
Antimalarialsa 1942 0 7268 0 REF 
a Subsets of “Full SLE”. Data on exposure from the Prescribed Drug Register 2006- 
b Adjusted for level of education, healthcare utilization, number of children, marital status, family 
history of cervical cancer, prior cervical screening, and start year. Models comparing SLE 
immunosuppressants vs. SLE antimalarials were additionally adjusted for use of oral 
contraceptives and oral steroids at baseline. 
c Hazard ratios were not calculated if there were less than 5 events in the smallest cell 
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Comparing the full SLE cohort to the general population comparators, the risk of a cervical 
neoplasia was higher, with a fully adjusted HR= 2.12 (95%CI 1.65-2.71) (Table 4.3). 
Secondary outcomes revealed increased risks of both LSIL and HSIL, but not of invasive 
cervical cancer (HR=1.64 (95%CI 0.54-5.02). When analyzing the outcomes according to 
drug exposures, we noted an almost doubled risk of a first neoplasia among 
immunosuppressants- treated, compared with antimalarials- treated (HR=1.83 95%CI 1.15-
2.91). Furthermore, all five cases of invasive cervical cancer were in the immunosuppressants 
cohort.  
Several sensitivity analyses were performed, stratifying the analyses on different age-bands, 
restricting to more recent SLE, adjusting for use of oral corticosteroids during follow-up etc. 
but these did not alter the interpretation of the main findings. 
4.4 STUDY III 
Study III was a cohort study in which we assessed the risk of incident malignancies 2006-
2015 in patients with RA treated with different bDMARDS. 
Exposure 
In ARTIS, we identified RA patients who during our study period, initiated treatment with a 
first TNFi, or a second TNFi, respectively, as well as three other bDMARD cohorts 
consisting of RA patients initiating a first tocilizumab-, abatacept-, or rituximab treatment. In 
addition, we defined a biologics-naïve comparator cohort consisting of RA patients treated 
with at least 1 csDMARD (methotrexate, leflunomide, azathioprine, cyclosporine, 
antimalarials, sulfasalazine, or gold). Through linkage of the bDMARD-treated cohorts to the 
Total Population Register, a general population comparator cohort was assembled.  
Outcomes 
We defined and assessed 5 separate outcomes: 1) a first invasive solid or hematologic 
malignant neoplasm, excluding NMSC, 2) a first invasive solid malignant neoplasm, 
excluding NMSC, 3) a first invasive hematologic malignant neoplasm, 4) a first invasive 
squamous cell skin cancer, 5) and a first invasive melanoma. 
Covariates and statistics 
End of follow-up was defined as first of 31 December 2015, death, emigration, date of any 
solid organ transplantation and occurrence of the outcome under study. In the main analysis 
the five bDMARD cohorts were assessed together with the csDMARD cohort as the 
reference. Relative risks were estimated using Cox regression, with follow-up time as the 
time-scale. In the full models, we adjusted for sex, start year, educational level, four 
comorbidities (ischemic heart disease; chronic obstructive pulmonary disease, diabetes 
mellitus, and previous knee/ankle/hip/shoulder-surgery), and healthcare utilization (number 
of hospitalizations and days spent in in-hospital care), sick-leave, disability pension, and 
baseline use of 1) oral prednisolone, 2) NSAIDs, and 3) and total number of prescription 
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drugs. Furthermore, because of missing data for the bDMARD-naïve patients, only analyses 
between different bDMARD cohorts were adjusted for HAQ, DAS28-CRP, erythrocyte 
sedimentation rate, CRP, and RA disease duration. Analyses between different bDMARD 
cohorts were also adjusted for prior bDMARD therapy. 
In addition to the main analyses, sensitivity analyses with alternative definitions of the 
bDMARD-naïve cohort were performed, one with no requirement of csDMARD-treatment, 
and one in which csDMARD-patients were followed from the date of switching or addition 
of a new csDMARD agent. To account for potential detection bias and reverse causality, 
another sensitivity analysis in which we added a 3-month lag period between start of 
bDMARD therapy, and start of follow-up, was performed.  
Main results of study III 
We identified a total of 15,129 initiations of TNFi as the first or second bDMARD, 1798 of 
tocilizumab, 2021 of abatacept, and 3586 of rituximab. Also, a comparator cohort of 46,610 
RA patients treated with csDMARDs were identified. There were some differences in 
characteristics at entry between the cohorts. For example, rituximab initiators were more 
often seropositive, and older, than other bDMARD initiators. Mean follow-up was shorter in 
the non-TNFi cohorts compared to the TNFi cohorts, owing to their more recent market 
introduction, and disease duration was longer. 
Adjusted for age, sex and stratified on start year, comorbidities and educational level, 
rheumatoid factor, number of hospitalizations and days spent in inpatient care (1987-), use of 
prednisolone at baseline, use of NSAID at baseline, number of prescription drugs at baseline, and 
sick leave and disability (yes/no) year before cohort entry, disease duration, DAS28-CRP, CRP, 
erythrocyte sedimentation rate, HAQ, and previous bDMARD therapy (yes/no).  
Table 4.4. Hazard ratios and 95% CI for the different outcomes under study in Swedish cohorts 
of patients with RA initiating tocilizumab, abatacept, or rituximab, ever treated analysis with 
incidences compared to those initiating TNFi therapy. 
Outcome definition, type of 
invasive malignancy 
Tocilizumab Abatacept Rituximab TNFi 
Solid/hematologic (no NMSC) 1.12 (0.81-1.54) 1.10 (0.82-1.48) 1.06 (0.86-1.30) REF 
Solid (no NMSC) 1.14 (0.81-1.59) 1.04 (0.76-1.42) 1.05 (0.84-1.31) REF 
Hematologic  1.82 (0.81-4.05) 1.12 (0.62-2.04) REF 
Squamous cell skin cancer 1.04 (0.39-2.80) 2.12 (1.14-3.95) 1.05 (0.62-1.77) REF 
Melanoma  2.39 (0.90-6.33) 1.07 (0.47-2.45) REF 
  37 
For the main outcome, a first invasive solid or hematologic malignant neoplasm excluding 
NMSC, we found no statistically significant risk difference between any of the bDMARD 
cohorts and the csDMARD cohort. The same was true for a first invasive solid malignant 
neoplasm excluding NMSC, a first invasive hematological malignancy, and a first invasive 
melanoma. For a first invasive squamous cell skin cancer, we found an increased risk among 
abatacept initiators, which was attenuated when adjusting for potential confounders, (fully 
adjusted HR=2.15, 95%CI 1.31-3.52).  
Alternative definitions of the bDMARD-naïve RA comparator cohort were investigated in a 
sensitivity analysis, with similar results as the main analysis. Also, adding a lag period 
between the start of treatment and start of follow-up, did not significantly alter the results. 
As a benchmark for the cancer rates in our RA cohorts, we calculated HRs comparing the 
csDMARD-treated cohort to the general population comparator cohort. The risk for the 
combined outcome of a first invasive solid or hematologic malignant neoplasm, excluding 
NMSC, was 1.11 (csDMARD vs. general population, 95% CI, 1.01-1.22), adjusted for age, 
sex, and start year. There was also an increased risk for a first invasive hematologic 
malignant neoplasm (HR, 1.56; 95%CI, 1.13-2.16), and a first invasive squamous cell skin 
cancer (HR,1.48; 95% CI, 1.03-2.13).  
4.5 STUDY IV 
Study IV was a combined cohort, and case-control study in which we assessed the risk of 
breast cancer in incident RA patients 2006-2016 (cohort), the risk of RA in women with a 
history of breast cancer (case-control), and the risk of RA in women with a history of breast 
cancer treated with anti-hormonal therapy (case-control). 
Exposure and outcomes 
In the analysis of breast cancer in patients with RA, we compared the incidence of breast 
cancer, invasive or in situ, in new-onset RA 2006-2016 to that of matched general population 
comparators.  
In the analysis of risk of RA in women with a history of breast cancer, we compared breast 
cancer exposure (invasive or in situ, 1958-) among incident RA cases, to that of matched 
controls from the general population. We then compared the risk of RA, between women 
with breast cancer that were treated with tamoxifen, or AI, respectively, to that of women 
with breast cancer that were not treated with these agents, and women without breast cancer.  
Covariates and statistics 
We assessed the crude incidence of breast cancer and performed Cox regression analysis, 
gradually adjusted for age, calendar year, educational level, country of birth, number of live 
births and age at first full-term pregnancy, previous invasive cancer, family history in a first-
degree relative of breast cancer or ovarian cancer, use of oral contraceptives and intrauterine 
devices, and HRT. Age 50 was used as a proxy for menopausal status. End of follow-up was 
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defined as December 31st 2016, death, emigration, or breast cancer, whichever occurred first. 
The risk of breast cancer was assessed overall, stratified by time since start of follow-up, by 
RA serostatus, and age at RA diagnosis. Furthermore, relative risks were assessed according 
to menopausal status, and TNM cancer stage.  
To assess the risk of RA in women with a history of breast cancer, we used a case-control 
design. Odds ratios (ORs) were computed using conditional logistic regression adjusted for 
the matching factors, country of birth, educational level, age at first live birth, number of live-
born children, and family history of breast- or ovarian cancer. The risk was assessed overall, 
by time between the breast cancer and RA, by menopausal status, TNM stage, age at RA 
diagnosis, and RA subtype.  
Finally, to assess the risk of RA associated with anti-hormonal breast cancer treatment (2005-
2016) we again used conditional logistic regression. We categorized subjects as tamoxifen 
only-treated, AI only-treated, both tamoxifen- and AI-treated, never tamoxifen- or AI-treated, 
and no breast cancer prior to index date. We also analyzed the risk with cumulative exposure 
of anti-hormonal treatment. To deal with detection bias, a sensitivity analysis in which we 
excluded subjects with less than one year between the breast cancer diagnosis and index date 
was performed. 
Main results of study IV 
We identified 15,921 incident patients with RA, who were matched on age, sex, and place of 
residence, with 79,441 randomly selected subjects from the general population. In both 
groups, mean age at baseline was 59 years, and 10% had a family history of breast- or ovarian 
cancer. Except for a somewhat lower level of education among RA patients (more than 12 
years of education, RA vs population referents, 15% vs. 19%), and a higher prevalence of 
family history of RA (10% vs 4%, RA vs population referents), characteristics at baseline 
were similar between the groups. 
During follow-up, we identified 190 cases of breast cancer among RA patients, and 1191 
cases among population comparators, fully adjusted HR=0.80 (95%CI 0.68-0.93). The fully 
adjusted model included age, calendar year, country of birth, educational level, HRT, oral 
contraceptives, age at first live birth, number of live-born children, family history of breast- 
or ovarian cancer, and previous invasive cancer, but the results were virtually unchanged by 
further adjustment beyond age and calendar year. There was no clear difference in risk 
among seronegative RA, HR=0.77 (0.58-1.02), as compared with seropositive RA, HR=0.81 
(0.67-0.98). Also, when the risk was assessed stratified by age at RA diagnosis, it was 
reduced for all age groups. When risks were assessed separately for each breast cancer stage, 
we noted reduced risks for all TNM stages. The risk was also reduced for both pre- and 
postmenopausal breast cancer.  
The risk for incident RA was lower in women with a history of breast cancer, and similar to 
that of breast cancer in RA, fully adjusted OR=0.87 (95%CI 0.79-0.95). ORs stratified by 
seropositive or seronegative RA, and age at RA diagnosis, yielded similar results as 
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compared to the main analysis. There was no clear trend when examining the risk by age at 
breast cancer diagnosis. Also, there was no clear trend when examining the risk of RA by 
TNM-cancer stage, albeit missing information on cancer stage was substantial, especially 
among earlier cases of cancer. 
During 2003-2016, there were 259 cases of breast cancer among RA patients, and 1499 cases 
among the controls. The OR for never (vs. ever) having received treatment with tamoxifen or 
AI (45% of RA cases, and 42% of controls), was 1.23 (95%CI 0.92-1.64)). Use of tamoxifen 
was somewhat more frequent than AI (n=629, vs n=565), with some overlap (n=184). The 
risk of developing RA among patients treated with both tamoxifen- and AI vs. never treated 
(fully adjusted OR=0.68 (95%CI 0.41-1.12). The risk among tamoxifen-only vs. never 
treated was OR=0.86 (95%CI 0.62-1.20), and among AI-only vs. never treated OR=0.97 
(95%CI 0.69-1.37).  
 
Figure 4.2. Relative risk of breast cancer other cancer in RA, as a function of time before (left of 
vertical line) and after (right of vertical line) RA diagnosis. RA vs. General population 
referents/controls, adjusted for age, country of birth and educational level 
When examining cumulative tamoxifen exposure (years) we noted no trend in risk of later 
RA. For AI, we noted an increased risk of later RA among patients treated with AI for less 
than 6 months (OR=1.58 (95%CI 1.02-2.45), but also a decreased risk with longer exposure 
time (>24 months OR=0.57 (95%CI 0.39-0.82). Restricting the analysis to cancer cases 
occurring after the PDR was started (July 2005- Dec 2016) yielded similar results as 
compared with the main analysis. Likewise, excluding subjects with less than one year 
between the breast cancer diagnosis and index date, also provided results similar to the main 
analysis.  
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5 DISCUSSION 
In this thesis, we have built upon previous knowledge and tried to further investigate and 
characterize the relationship between chronic inflammation, in the context of autoimmune 
rheumatic disease, and cancer. Using epidemiologic methods, we have shown that there is an 
increased risk of cervical neoplasia, albeit perhaps not invasive cancer, in women with RA, 
and, whether causal or not, that the risk is higher in patients treated with TNFi. Likewise, we 
have shown that women with SLE are at higher risk of developing cervical neoplasia, and 
that the risk is especially high in women treated with immunosuppressant therapy. 
Furthermore, we have added to the growing evidence of the short and medium term safety of 
TNFi, in terms of overall malignancies, and, albeit with less certainty, also found this to be 
true for tocilizumab, abatacept, and rituximab. We found a signal of an increased risk of 
squamous cell skin cancer for RA patients treated with abatacept. We have also shown that 
the risk of breast cancer for women with RA is reduced, and likewise that the future risk of 
RA in women with breast cancer is also reduced, and that these risk reductions did not seem 
to be explained by known breast cancer risk factors. Finally, we could not find evidence to 
support that tamoxifen, or AI, increases the risk of developing RA. 
As has been described in this thesis, examining the risk of malignancies associated with 
rheumatic diseases and their treatments, is a complicated matter. Although observational 
studies are inherently equipped with significant limitations, they are the best option we 
currently have to answer these questions. RCTs are equipped with great strengths, such as a 
proper comparator that is balanced in terms of known, and unknown confounders. However, 
when examining rare long-term outcomes, several points argue against the use of RCTs. The 
patients that are presumably at the highest risk of developing cancer are often excluded, such 
as those with a previous malignancy, or those with anemia or other pathological lab-values of 
unknown origins. The study period is typically too short to investigate risks with long 
induction times, and open-label extensions lack a proper reference group. Other options, such 
as spontaneous reporting of adverse events by physicians, can detect important signals, but 
proper incidence rates cannot be computed due to large uncertainties in both the numerator 
(e.g. underreporting), and the denominator (unknown person-time at risk).  
The fact that these are chronic conditions, use of the drugs in our studies will often be long-
term, and in some cases lifelong. This highlights the importance of safety, and the need for 
long-term studies. Moreover, although it is comforting that there is only a minor risk increase 
of overall cancer in patients with RA, as we have seen in this thesis, this picture can be 
further nuanced. Cancer is a loaded term, but it can encompass everything from very mild 
disease that will have no detrimental effect on survival, to aggressive tumors that can cause 
sudden death. The lifetime risk of developing breast cancer for Swedish women is higher 
than 1 in 10, thus a 20% reduced risk will have a large impact (35). To further highlight the 
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clinical relevance we can compare this to cardiovascular risks in RA, which are well-known. 
For comparison, the risk of breast cancer in women 55-65 years old is 2-3 times higher than 
that of myocardial infarction. Unfortunately, given that there is only a minor risk increase for 
cancer overall, a lower risk of breast cancer, with a 5-year relative survival rate of 92%, 
means that there must be a higher risk for other cancers. For women, the 5-year relative 
survival for overall cancer is 74%, and for lung cancer, which is more common in patients 
with RA, it is an appalling 24% (35). 
5.1 BDMARDS AND CANCER 
Study III is one of the largest studies on the risk of malignant neoplasms in RA patients 
treated with bDMARDs to date. We found that there was no increased risk of solid, 
hematologic, or skin cancers with TNFi-treatment in RA. This was in line with the vast 
majority of previously published studies, including both RCTs and observational studies (63, 
64). Our study added to this previous knowledge, and showed that the risk was still not 
increased in a more contemporary cohort, and with longer follow-up. Furthermore, there was 
no increased risk of overall malignancies in patients treated with other bDMARDs, with 
upper confidence limits ruling out clinically meaningful risk increases. These findings were 
in line with previous reports. However, before the publication of this study, there was limited 
data available from observational studies on the safety of non-TNFi bDMARDs, and most of 
data came from RCTs (80-82). We found no data on tocilizumab, but the limited 
observational data on rituximab, or abatacept, had shown no increased risk of overall 
malignancies (47, 83, 84). One of these studies found an increased risk of NMSC (which 
includes squamous cell skin cancer) in abatacept-treated, compared to methotrexate-treated, 
although based on only 5 events in the abatacept group. The only statistically significant risk 
increase we found in Study III, was that of invasive squamous cell cancer in abatacept-
treated (fully adjusted HR=2.15 (95%CI 1.31-3.52)). Our result was attenuated by adjusting 
for confounders, and might be subject to residual confounding. Indeed, the age- and sex 
adjusted rates was considerably higher in all the RA exposure groups, compared to the 
general population referents. Studies published after Study III have confirmed the absence of 
an increased risk of overall cancer in RA patients treated with tocilizumab (159). Regarding 
abatacept, studies published after Study III, have both confirmed, and contradicted our 
results. Two recent studies utilizing data from different US claims- and healthcare databases, 
have found that abatacept initiation in RA was associated with a slightly increased risk of 
overall cancer (15-20%), with upper confidence limits below 1.4 (160, 161). The second of 
these two studies also found a 20% increased risk for NMSC in abatacept initiators, 
compared with other bDMARDs (161). However, as there were some noticeable baseline 
differences in both studies including comorbid conditions and baseline medications, between 
abatacept-, and other bDMARDs-treated, these results might be subject to residual 
confounding. Furthermore, identification of incident cancers, bDMARD-exposure and 
baseline comorbid conditions was limited to data that were captured in the medical record or 
claims. Another recent report from the observational US FORWARD study found no 
increased risk of overall malignancy for abatacept, compared to other bDMARDs or 
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csDMARDs (162). A collaborative effort using data from ARTIS, and the FORWARD study, 
and thus partly overlapping with other studies, as well as German, and Canadian data, found 
no risk difference for solid tumors, between abatacept and other bDMARDs (pooled estimate 
1.0, 95%CI 0.8-1.3) (163). In Study III, we did not find a statistically significant risk 
increase for melanoma in abatacept initiators, although based on only 7 events, and the crude 
and adjusted rates was highest in this group. A recent publication conducted on WHO's 
global database of individual case safety reports (Vigibase®), found a 50% increased risk of 
reporting melanoma, but not overall cancer, in abatacept- compared to other bDMARDs-
treated RA (164). As the authors discuss, this is consistent with the pharmacodynamic 
properties of abatacept, although this might perhaps lead to biased spontaneous reporting of 
events. In contrast to Study III, the Vigibase study was not able to adjust for any 
confounders, and as previously mentioned in this thesis, spontaneous reporting of adverse 
events leads to uncertainties in the person-time at risk. In conclusion, although there are 
question marks in terms of risk of cancer with abatacept-use, especially for skin cancers, most 
studies indicate that the short- and medium term risk of cancer is not increased.  
5.2 CERVICAL NEOPLASIA 
In Study I we made a series of important observations: There was a slightly elevated risk of 
cervical dysplasia, but not invasive cervical cancer, in biologics-naïve women with RA 
compared to the general population. The risk of HSIL, but not LSIL, was slightly higher in 
TNFi-treated, compared to biologics-naïve RA, and the risk of invasive cervical cancer was 
doubled. Furthermore, intensity of cervical screening was slightly higher in women with RA, 
but did not differ between TNFi-treated and biologics-naïve RA. In Study II we found that 
SLE is a risk factor for cervical neoplasia, overall, and for pre-malignant cervical lesions in 
particular. Additionally, we found that the risk is higher among those treated with systemic 
immunosuppressants, compared with antimalarials treated. We did not find evidence to 
support that there were any major differences in cervical screening that could explain these 
findings.  
In Study I we found an increased risk of both HSIL and LSIL, but not of invasive cervical 
cancer, in biologics-naïve RA compared to general population comparators. However, the CIs 
for the different outcomes overlapped each other. Seeing as invasive cervical cancer was a 
rare outcome in our population of mostly screened Swedish women, the absence of an 
increased risk for cervical cancer in RA might thus be due to chance. If we combine HSIL 
and invasive cervical cancer, our results are similar to that of the study by Kim et al., which 
found a 50% increase of that outcome for women with RA, compared to women without 
systemic autoimmune disease (97). On the other hand, most previous studies on RA and 
invasive cervical cancer have found no association, the meta-analysis by Simon et al. reported 
an SIR of 0.87 (95% 0.72, 1.05) (46).  
In Study II we found a doubled risk of cervical neoplasia in women with SLE, compared to 
the general population comparators. The risk was further doubled in women treated with 
immunosuppressants, compared to those treated with antimalarials. Our results were similar 
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to that of the study by Kim et al., which reported a 50-100% increased risk of HSIL and 
cervical cancer in women with SLE, compared to women without systemic autoimmune 
disease (97). Although most studies have found an increased risk of cervical dysplasia in 
women with SLE, the doubled risk we observed was a lot lower than the 9-fold risk increase 
reported in a meta-analysis by Zard et al. (102) However, the studies included were 
conducted in countries with very big differences in incidence and screening of cervical cancer 
compared to Sweden. We found no statistically increased risk of invasive cervical cancer, but 
the CI was too wide to rule out a clinically significant risk increase (HR=1.64, 95%CI 0.54-
5.02). Several previous reports have found no significant risk increase in SLE (18, 103, 104). 
A Canadian cohort study with follow-up between 1975 and 1994, found an elevated risk for 
cervical cancer (SIR=8.15, 95% CI: 1.63–23.81). On the other hand, a large register-based 
study from California with follow-up between 1991 and 2002 reported an SIR of 0.55 
(95%CI 0.39–0.75) (105). Many of the previous studies are quite old and have not taken 
cervical screening, or other potentially important confounders, into account. Results might 
therefore not be generalizable to present conditions, both in terms of management of SLE, 
and of cervical neoplasia. In a more similar setting to that of our study, a Danish study by 
Dreyer et al. found a doubled risk of cervical dysplasia in SLE. They also reported a doubled 
risk of HPV-associated cancers, but the study was not powered to rule in- or out clinically 
meaningful risk differences for invasive cervical cancer (SIR=0.6 (95%CI 0.1–4.5)) (165). In 
agreement with our findings, previous studies have found that treatment with 
immunosuppressants in SLE is associated with a higher risk of cervical dysplasia (166-168). 
A study based on US insurance data published after ours, compared the risk of HSIL or 
cervical cancer in women with SLE that initiated treatment with immunosuppressive drugs to 
that of antimalarials-treated, and found an HR of 1.40 (95% CI 0.92–2.12) (169) A register-
based study from Denmark on women with autoimmune disease found a dose-dependent risk 
increase of cervical cancer with azathioprine, but no association with immunosupressants in 
general (103). Thus it seems like women with SLE treated with immunosuppressants are at a 
higher risk of cervical neoplasia, but whether this is due to the indication, or the exposure, is 
not clear.  
As previously described in the background section, invasive cervical cancer is caused by 
persistent HPV infection, via precancerous dysplasia. The aim of cervical screening is to 
detect, and treat, pre-cancerous lesions before invasive cervical cancer develops. Almost all 
precancerous lesions that are diagnosed are detected through this screening process, and if left 
untreated, most of these lesions spontaneously regress. Thus a higher screening intensity will 
increase the incidence of cervical dysplasia, and decrease the incidence of invasive cervical 
cancer. On the other hand, a lower screening intensity will decrease the incidence of 
dysplasia, and increase the incidence of invasive cervical cancer. A recent study from the 
British biologics register found higher rates of LSIL, and lower rates of HSIL, in women with 
RA compared to the general population, which might be due to the higher rates of screening 
that they observed in women with RA (170). Our measure of screening intensity revealed 
similar rates of screening between women with RA, with or without TNFi treatment, and the 
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general population. In SLE, we noted some small numerical differences between SLE and the 
general population comparators, and between antimalarials- and immunosuppressants-treated 
SLE. With the high rates of cervical neoplasia in immunosuppressants-treated SLE in mind, it 
is somewhat worrying that we observed lower age-adjusted rates of screening in this group 
compared to antimalarials-treated, although not statistically significant. The differences in 
screening, in both Study I and II, might have been too small to explain differences in the 
crude rates of cervical neoplasia, and regression models were adjusted for previous screening. 
On the other hand, time to first screen might be too crude a measure to detect clinically 
meaningful differences in screening. A more thorough examination could perhaps reveal 
differences in the timing or the reasons for screening. For example, we did not discriminate 
between opportunistic or pre-planned screening. Our finding that women with SLE did not 
have lower rates of screening than the general population contrasts that of a Canadian study, 
which found a lower rate of self-reported cervical screening among women with SLE, 
compared to community rates (106). Likewise, some previous studies from the US have 
reported suboptimal screening in RA (108, 109). As previously mentioned, the study from 
British biologics register, found higher rates of cervical screening in women with RA, but 
lower rates in those with high HAQ-values (170). A register-based study conducted in 
Denmark, with a similar healthcare and cervical screening system to that of Sweden, 
observed similar screening rates among both SLE, and RA patients, as compared with the 
general population (103). Thus screening uptake in women with RA and SLE might differ 
between countries and might be dependent on patient disability.  
The finding of an increased risk of invasive cervical cancer in TNFi-treated compared to 
biologics-naïve RA was a novel finding, and perhaps somewhat unexpected. Although there 
is a biologic rationale behind why TNFi could theoretically increase the risk of cervical 
cancer, previous studies on TNFi and aspects of cervical malignancy had shown no such 
association (53, 100, 101). The previous studies were perhaps not powered to rule out 
clinically significant risk increases, due to the low background risk of cervical cancer, and the 
fact that the latter two conditioned on a previous cervical lesion. Since Study I was 
published, a large US cohort study found a 1.3 times higher risk of the combined outcome of 
cervical dysplasia or cervical cancer, albeit not statistically significant, comparing bDMARD-
treated to non-bDMARD-treated RA (171). Our finding of a doubled risk of invasive cervical 
cancer would correspond to one additional annual case for every 7000 treated women, which 
needs to be weighed against any benefit of TNFi treatment or its alternatives.  
Comparing cancer risks between different RA treatments, over time and across different 
countries, is like trying to hit a moving target. The indication for bDMARD-treatments have 
widened over time. As shown by Figure 1.2, HAQ and DAS28 values in bDMARD-initiators 
have decreased over time. Also, non-bDMARD treatment patterns have changed, e.g. with 
the ascent of methotrexate as a cornerstone of RA treatment. This means that the cumulative 
exposure to other treatments in a biologics-naïve comparator, or previous and concomitant 
exposures in patients starting bDMARD-treatment, differ between modern cohorts and past 
cohorts. The use of biomarkers and criteria in diagnosing disease can also modify the 
  45 
sensitivity or specificity of diagnosis, as well as the time point in the disease trajectory that 
the diagnosis is made. If, e.g. disease severity or disease duration is associated with the risk of 
developing cancer, this muddles the comparison of risk estimates in different studies. Thus, 
there might be powerful selection, to- and away from, different therapies, that is further 
complicated by changes over time. On this subject, an interesting observation in Study I, was 
that only 1 out of 14 cases of cervical cancer was reported in more contemporary initiators of 
TNFi (2006-). In the same analysis, all point estimates (LSIL, HSIL, and invasive cervical 
cancer) for TNFi moved towards lower risks, while all point estimates for the biologics-naïve 
cohort, compared to the general population, moved towards increased risks. In analogy to 
this, previous reports from ARTIS with follow-up through 2010 had found an increased risk 
of invasive melanoma in TNFi-treated vs. biologics-naïve RA (72). However, in Study III, 
with follow-up from January 2006 to December 2015, we found no risk difference between 
initiators of TNFi and biologics-naïve, with a point estimate that was below 1 (HR=0.84, 
95%CI (0.60-1.18)). Admittedly, this could well be down to chance, or different biases. On 
the other hand, there is also the possibility that there has a been a shift, over time, in the 
channeling of patients at high risk of cervical neoplasia or melanoma, away from TNFi, and 
towards csDMARDs, and that our models were unable to fully handle this confounding by 
indication.  
5.3 BREAST CANCER 
The finding in Study IV of a 20% decreased risk of breast cancer in women with a history of 
RA, was in line with former studies, that had not adjusted for breast cancer risk factors (46). 
The risk of RA in women with a history of breast cancer was also reduced, in order of the 
same magnitude. No previous study had focused on this association, but a similar result was 
published as comparison in a study of the risk of lymphoma in RA, using the same Swedish 
registers, but with only partly overlapping data (early onset RA 1997-2006 vs. 2006-2016) 
(121). As previously mentioned, management of RA has evolved greatly over the last 
decades. New drugs have been introduced, and the approach to therapy has changed. There 
has been a shift in paradigm from “go low, go slow”, to aggressive early treatment with 
efficient DMARD therapy, with the goal of remission. During this period, mammographic 
screening for breast cancer has become well-established, partly reflected in a doubling of the 
age-standardized incidence of breast cancer in Sweden since the 1970-s (35). With this in 
mind, it’s remarkable how stable the relative risk of breast cancer in Nordic women with RA 
has remained. In a study on cancer risk in Swedish RA patients with follow-up from 1964-
1984, the risk was 0.79 (0.6-1.0)(44), and in a study on Danish RA patients with follow-up 
from 1978-1991 the risk was 0.8 (0.7-0.9) (45). In another Swedish study with follow-up 
between 1990-2003, the risk was 0.83 (0.76-0.91) (42). Study IV had follow-up between 
2006-2016, and found a 0.80 (0.68-0.93), with a similar decreased risk of RA in women with 
a history of breast cancer. Furthermore, there was no clear trend when examining TNM-stage 
of breast cancer, which could have reflected a detection bias. Taken together, this would 
argue against the hypothesis that the decreased risk of breast cancer in patients with RA is 
due to RA, or RA treatment.  
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Our models were adjusted for several potential confounders, including hormonal risk factors, 
but this had a very limited impact on the results. We observed that these risk factors were 
indeed risk factors for breast cancer in our study population, but they were only weakly 
associated with RA (Supplement Study IV). If not due to these shared risk factors, although 
the possibility of unmeasured or residual confounding remains, shared genetics between RA 
and breast cancer would be another explanation. Some findings, including polymorphisms of 
cyclooxygenase-2 and DRB1, could perhaps partly explain the inverse association (172-174). 
However, without GWAS-studies, it’s hard to quantify the net effects of these genetic factors. 
A perhaps noteworthy finding in Study IV was the similarity in breast cancer HR between 
seropositive RA, and seronegative RA, in terms of breast cancer risk. Seronegative RA is 
often thought of as a subset of RA with partly different etiology and presentation, and 
misclassification between seronegative RA and other conditions (including seropositive RA) 
is considered prevalent. Furthermore, an inverse association of the same magnitude has been 
reported between breast cancer and SLE (175). A study using GWAS-data could not find 
strong evidence for shared genetic causes as an explanation, albeit only 10 SLE-associated 
SNPs were investigated (176).  
We examined the risk of developing future RA with tamoxifen- and AI-use, and in contrast to 
previous studies, we found no such association (143, 144). The study by Chen et al. included 
more than 200,000 cases of breast cancer, and found an increased risk of RA with both 
selective estrogen receptor modulators, including tamoxifen, and also with AI, compared to 
women with breast cancer who did not receive these treatments. Although the size of the 
study is impressive, some important limitations should be mentioned. Firstly, the study did 
not take follow-up time into account, if the mean time of follow-up differs between the 
groups then differences in the cumulative incidence might not reflect differences in the 
incidence rate. Secondly, they were unable to adjust for any confounders, most importantly 
age. Since the decision whether to administer treatment with tamoxifen or AI is affected by 
menopausal status and the age of the patient, and age is an important risk factor for RA, this 
might be an important confounder. The study by Caprioli et al. found an increased risk of RA 
among breast cancer patients treated with AI, compared to those treated with tamoxifen. 
However, they did not compare these rates to that of patients not treated with anti-estrogens 
or to that of the general population. The incidence rate of RA that they observed (4.33 per 
1000 person-years), is somewhat lower than population-based age- and sex standardized 
incidence rates reported from Italy (127), and Sweden (1). 
5.4 FURTHER METHODOLOGICAL CONSIDERATIONS 
All four studies in this thesis were based on national registers with prospectively collected 
data with a high degree of validity and coverage. All cancer outcomes were identified 
independently of exposure and of the treating rheumatologist. We were able to account for 
TNM-cancer stage at diagnosis, which could reveal a potential detection bias. When 
assessing the risk of malignancies associated with different pharmaceutical treatments, we 
benchmarked these risks to matched general population comparator cohorts. When feasible, 
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we used active-comparator designs, which provides a more clinically relevant comparison 
and reduces confounding. Utilizing the rich source of data in the Swedish setting, we adjusted 
our models for several potentially important confounders, which were decided a priori. 
Diagnoses were identified using previously described, partly validated, algorithms.   
Incomplete information concerning disease activity and disability, such as HAQ and DAS28 
measures, was a limitation in Studies I-III. In Study III we could use the information in 
ARTIS to adjust for HAQ and DAS28 in comparisons between different bDMARD exposure 
categories, but not in comparisons with biologics-naïve RA. In Study II, although there are 
measures for monitoring of disease activity in SLE, we did not have this data. We lacked 
information on smoking and BMI, which could be potential confounders in all four studies. 
Adjustments for chronic obstructive pulmonary disorder in Studies I and III might capture 
some of the potential confounding due to smoking, but must be considered a poor proxy. On 
the other hand, previous reports from a Swedish RA study reported only minor differences in 
the prevalence of smoking between biologics-naïve-, and bDMARD-treated, RA (177). In 
Study II, we chose to perform a quantitative bias analysis on the potential impact of 
smoking. We found that even if we assumed extreme values for the prevalence of smoking 
among women with SLE, it could only explain part of the observed association. Another 
limitation was left truncation in the PDR (started in 2005), and in the outpatient-subset of the 
NPR (started in 2001). In Study III, we adjusted for sick-leave and disability pension at 
baseline with data from the Social Insurance Agency (Försäkringskassan). Short periods of 
sick-leave, less than 15 days, are not recorded and thus not accounted for in our analysis, 
because they are covered by the employer rather than the Social Insurance Agency. However 
sick-leave periods in RA are typically not short. A study from Finland published in 2006, 
with a similar social security system to that of Sweden, found that only 3.5% of sick leave 
periods in RA were 10-days or shorter (178) 
In Study IV we did not have data on menarche, menopause or breastfeeding. We used age 50 
as a proxy for menopause, which has been reported as the mean age of menopause in 
Swedish women, with a standard deviation of 3.77 (179). We did not account for HPV 
vaccination, which was introduced in 2006, during the study period of both Studies I-II. 
However, at the end of the study period, only about 2,5% of Swedish girls and women were 
vaccinated (180). In our study populations, consisting of mostly middle-aged women, 
penetrance would be expected to be even lower. Left truncation of the outpatient register 
could have resulted in misclassification of the disease under study or comorbidities. 
Furthermore, although coverage of prescribed drugs dispensed at a pharmacy is excellent, it 
typically does not capture drugs administered during a clinical visit. This means that coverage 
for infusion drugs such as rituximab, infliximab and cyclophosphamide, is presumably low. 
In Studies I and III we could identify these drugs in ARTIS. In Study II, where the study 
population consisted of SLE patients, this option was not available. However, since we 
grouped immunosuppressants together, and there was substantial overlap between 
immunosuppressant therapies, most of these patients would have been included under another 
drug. The fact that patients may have been exposed to multiple other pharmaceutical agents, 
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which may be associated with risk increases for malignancies that are not only short-term, 
prior to or after start of treatment of the drug under study made it hard to disentangle drug 
specific risks in Studies I-III. In Study III, 80% of the patients initiating treatment with 
other bDMARDs than TNFi had previously been treated with TNFi, and presumably failed 
on that treatment. We therefore defined an additional cohort of patients starting a new TNFi 
as their second ever bDMARD, as a perhaps more clinically relevant comparator. We also 
conducted analyses adjusted, or not, for previous TNFi-use, with similar results. However 
previous exposure to csDMARDs, could have varied between the groups, and this might be 
associated with long term effects on the outcome. The relatively recent introduction of non-
TNFi bDMARDS, and to a lesser extent of TNFi, precluded analysis of long-term risks. 
Furthermore, our decision to group all TNFi together, with the bulk of the data coming from 
etanercept, adalimumab, and infliximab, might have concealed agent-specific risk differences 
in Study I and III. As a result of the nationwide design adopted in all studies in this thesis, 
we were able to assemble large study populations. Nevertheless, lack of statistical power in 
some cases forced us to study composite outcomes, and for some of the rare outcomes, such 
as invasive cervical cancer (Studies I-II), and invasive melanoma (Study III), statistical 
power was indeed a limitation. It could be argued that some studies should be postponed until 
enough follow-up time has accrued to more definitely answer the specific research question. 
However, for serious adverse events, such as malignancies, the urgency might preclude 
further waiting, and even though estimates will be imprecise, even smaller studies may be 
able to rule out clinically meaningful risk increases.  
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6 CONCLUSIONS 
Linkage of national Swedish registers and quality of care data provides a good platform for 
studying the occurrence of cancer in rheumatic disease, with patient populations of sufficient 
sizes to investigate even relatively rare outcomes. The richness of the data sources allows for 
detailed comparisons within treatment defined patient subgroups, which can address several 
potentially important sources of bias. Our findings may provide answers to a number of 
scientific questions, including both etiologic and exploratory questions. Specifically, we 
found that: 
 Women with RA are at higher risk of cervical dysplasia, but perhaps not cervical 
cancer.  
 Women with RA starting treatment with TNFi are at higher risk of cervical dysplasia 
and cervical cancer. 
 Women with SLE are at higher risk of cervical neoplasia, in particular pre-malignant 
lesions. Those that are treated with immunosuppressants are at higher risk than those 
treated with antimalarials.  
 Women with RA and SLE have similar rates of cervical screening as the general 
population. Screening does not seem to explain the higher rates of cervical dysplasia 
in RA and SLE.  
 Patients with RA exhibit both higher and lower rates of site specific cancers but the 
net effect appears to be a slightly increased risk of overall cancer. The reasons behind 
these associations are not well established but are likely to involve causes related to 
both the disease and its treatment, as well as factors not directly related to RA.  
 The overall risk of cancer among patients with RA initiating TNFi as first or second 
bDMARD, tocilizumab, abatacept, or rituximab does not differ substantially from that 
of biologic drug–naive, csDMARD-treated patients with RA. With some possible 
exceptions, bDMARDs appear safe in terms of cancer risks although site-specific 
risks are not well-examined, and long-term risks are still unknown.  
 The risk of squamous cell skin cancer in RA patients starting treatment with abatacept 
is increased, a finding which calls for replication. Whether causal or not, caution is 
adviced for those with risk factors for skin cancer, and periodical skin examination 
could be warranted. 
 There is a decreased risk of breast cancer in patients with RA, and a similar decrease 
in risk of RA in patients with a history of breast cancer. This does not seem to be 
readily explained by known risk factors for breast cancer. These findings suggest that 
other factors, independent of RA, drive the inverse association between the two 
diseases. 
 Tamoxifen and AI as used in adjuvant breast cancer treatment does not seem to 
increase the short or medium term risk of RA. Long term risks, as well as the risk for 
inflammatory joint disease other than RA, are unknown.  
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7 FUTURE STUDIES 
Although the studies described in this thesis have answered some important questions, it has 
also raised and highlighted some new questions. Here I have outlined some thoughts about 
future studies, some of which are already planned:  
Studies I-II 
Cervical cancer incidence in Sweden is low, and will hopefully continue to decrease due to 
HPV-vaccination and more efficient screening methods. However, globally it is still ranked 
4th in cancer incidence in women, with more than half a million new cases every year. This 
means that cervical cancer as a comorbidity in rheumatic disease, will still be relevant for the 
foreseeable future. Although we did find an increased risk with TNFi in RA, this result calls 
for replication. As for the increased risk among immunosuppressants-treated in SLE, the 
extent to which this was caused by the medication, or the disease itself, was hard to 
disentangle. Future studies could address this issue in more detail. A greater understanding of 
these risks is also called upon in light of the fact that some guidelines now suggest more 
intensive screening in all women with SLE, and in some women with RA (181). Stressing the 
need for cervical screening in women potentially at increased risk seems justified, especially 
for those not adherent to screening guidelines. However, excessive screening can divert 
recourses away from more urgent needs, as well as cause unnecessary discomfort for the 
patient. Therefore, studies that can identify more specifically, in terms of e.g. disease severity 
or pharmaceutical agents, which women that we need to monitor more closely, are needed.  
Study III 
Although the evidence for short and medium term cancer risks with TNFi seems reassuring, 
owing to their recent introduction, long term risks are still inherently unknown. The question 
mark regarding the safety of abatacept in terms of risk for skin cancer, needs to be further 
investigated. As it stands, heightened surveillance or caution in patients at increased risk of 
skin cancer, e.g. those with a previous skin cancer, could be warranted. Furthermore, as new 
pharmaceutical agents are introduced in rheumatology, targeting new inflammatory 
pathways, the need for post-market surveillance studies continues.  
Study IV  
We found in this study that the risk of breast cancer was lower among women with RA, and 
that women with breast cancer had a lower risk of developing RA. We did not find evidence 
to support that this was due to socioeconomic- or parity- related factors. We did not 
investigate if the risk reduction was due to shared genetic factors between breast cancer and 
RA. Future studies examining the risk in siblings to patients with RA, or GWAS-studies, 
could help us further elucidate the origins of this association. Furthermore, although 
differential screening was not apparent when examining stage at detection between women 
with RA and population controls, this could not be ruled out, and should be examined in the 
future, incorporating mammographic screening, and mammographic density.  
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ 
SVENSKA 
Syftet med den här avhandlingen var att fördjupa vår kunskap kring sambandet mellan 
reumatisk sjukdom, dess behandling, och cancer. Reumatisk sjukdom karaktäriseras av 
kronisk inflammation. Inflammation är immunförsvarets sätt att hantera kroppsfrämmande 
substanser eller organismer. Akut inflammation är ofta av godo, men kronisk inflammation 
tyder på att något har gått fel i immunförsvaret, att t.ex. immunförsvaret uppfattar kroppsegna 
substanser som främmande. Det har varit känt sedan 1800-talet att kronisk inflammation är 
kopplat till cancer och senare upptäckter har visat att det finns ett direkt orsakssamband 
mellan kronisk inflammation av många sorters ursprung, inklusive reumatisk sjukdom, och 
olika typer av cancer. Att studera sambandet mellan reumatisk sjukdom och cancer 
kompliceras av det faktum att det är svårt att bena ut vad som är orsakat av sjukdomen i sig, 
och vad som är orsakat av behandlingen. I slutet av 1900-talet började det komma nya sorters 
behandlingar som var riktade mot specifika komponenter i immunförsvaret, såsom 
signalmolekyler, istället för att slå brett på immunförsvaret. Ur biverkanssynpunkt är riktade 
behandlingar ofta att föredra, men behandlingar som riktar sig mot signalvägar som är 
inblandade i kroppens försvar mot cancertumörer kan vara förknippade med specifika 
biverkningar. Inom reumatologin kom de så kallade TNF-hämmarna under 90-talet som 
verkar på detta sätt, genom att blockera en signalmolekyl i immunförsvaret. Denna och andra 
behandlingar har visat sig mycket effektiva och har revolutionerat behandlingen av 
ledgångsreumatism. Problemet är att immunförsvaret är mycket komplext, vi vet helt enkelt 
inte riktigt vad som i övrigt sker i kroppen när vi går in och manipulerar dessa signalvägar 
och processer. Experimentella studier på t.ex. människoceller eller djur är en viktig pusselbit i 
jakten på en större förståelse, men det behövs även studier i levande människor. 
Randomiserade kliniska prövningar, där patienter slumpvis väljs ut till en behandling anses 
ha ett högt bevisvärde men lämpar sig av olika skäl dåligt för att studera ovanliga utfall som 
uppstår långt efter behandlingsstart. Därför måste vi ofta förlita oss på så kallade 
observationella studier, som utgår från vad som faktiskt har hänt i patientpopulationen, utan 
att manipulera exponeringen. I Sverige har vi en lång tradition av att samla information om 
invånarna i olika register, såväl demografiska som hälso- och sjukdomsregister. Denna 
avhandling har med epidemiologiska metoder, med hjälp av dessa register, undersökt risken 
för olika cancerformer bland patienter med ledgångsreumatism, och systemisk lupus 
erythematosus (SLE). Tack vare den rikliga informationen i dessa register kan vi identifiera 
dessa patientpopulationer, och jämförbara kontrollpopulationer från den övriga befolkningen. 
Vi kan följa dem över tid, från diagnos till eventuell cancer, migration, död o.s.v. Vi kan till 
detta addera information om vilka behandlingar som de har förskrivits utav läkare, eller 
hämtat ut på apotek. Genom att inkorporera information om t.ex. utbildningsnivå, 
sjukskrivning, eller annan samsjuklighet, kan vi justera för faktorer som kan tänkas störa 
skattningen av sambandet mellan reumatisk sjukdom, reumatisk behandling, och cancer.  
I Studie I undersökte vi om behandling med TNF-hämmare hos patienter med 
ledgångsreumatism ökade risken för livmoderhalscancer, eller förstadier till 
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livmoderhalscancer. Då det finns möjlighet att screena för livmoderhalscancer undersökte vi 
dessutom i vilken utsträckning dessa patienter screenade sig. För dessa utfall jämförde vi 
denna grupp patienter med andra patienter med ledgångsreumatism som inte hade behandlats 
med TNF-hämmare. Dessutom jämförde vi dessa utfall mellan kvinnor med 
ledgångsreumatism som inte hade behandlats med TNF-hämmare, med matchade kontroller 
från den övriga befolkningen. Vi kontrollerade för flera potentiella störfaktorer, såsom ålder, 
utbildningsnivå, civilstånd, tidigare screening, andra sjukdomar och sjukvårdsanvändning. Vi 
fann en 40-50% ökad risk för förstadier till livmoderhalscancer, men inte för faktisk 
livmoderhalscancer, hos kvinnor med ledgångsreumatism som inte hade behandlats med 
TNF-hämmare, jämfört med befolkningskontroller. Vi fann även att dessa kvinnor screenade 
sig i större utsträckning än kontrollerna, men skillnaden var endast marginell. För patienter 
behandlade med TNF-hämmare fann vi en 20-40% ökad risk för förstadier till 
livmoderhalscancer, samt en dubblad risk för faktisk livmoderhalscancer, jämfört med övriga 
ledgångsreumatiker. Vi fann ingen nämnvärd skillnad i screening mellan de två 
patientgrupperna. En ökad risk för livmoderhalscancer förknippad med TNF-hämmare har 
inte rapporterats från andra studier. Även om vi kunde justera för många potentiellt viktiga 
störfaktorer, så kan riskökningen ändå vara ett resultat av kvarvarande systematiska fel eller 
helt enkelt vara ett slumpfynd. Vi var därför försiktiga i vår tolkning av detta fynd. 
I Studie II var syftet att studera risken för förstadier till livmoderhalscancer, och faktisk 
livmoderhalscancer, samt följsamhet till screening, bland kvinnor med SLE, överlag och i 
relation till SLE-behandling, och att jämföra denna risk med befolkningskontroller, samt att 
även undersöka följsamheten till screening. Genom att länka olika register kunde vi 
identifiera en grupp kvinnor med SLE, dela upp denna grupp i två subgrupper baserade på 
hur aggressiv behandling de erhöll, och även identifiera matchade befolkningskontroller. Vi 
kontrollerade våra analyser för möjliga störfaktorer, såsom ålder, utbildningsnivå, 
sjukvårdsanvändning, civilstånd, antalet barn, och tidigare screening. Vi fann en fördubblad 
risk för förstadier till-, eller faktisk livmoderhalscancer, bland kvinnor med SLE jämfört med 
kontroller. Vi fann att risken var ännu högre bland de patienter som erhållit mer aggressiv 
behandling. Följsamheten till screening skiljde sig inte nämnvärt åt mellan grupperna. Vi 
kunde inte bena ut om den höga risken i gruppen med mer aggressiv behandling berodde på 
behandlingen, eller på sjukdomen i sig. Vi drog dock slutsatsen att oavsett detta så är det av 
vikt att kvinnor med SLE skyddas mot cervixcancer genom screening och vaccinering. 
I Studie III undersökte vi risken för cancer bland ledgångsreumatiker som behandlats med 
TNF-hämmare, eller med tre andra nya riktade läkemedel (abatacept, rituximab, och 
tocilizumab), och jämförde den med patienter med ledgångsreumatism som inte hade 
behandlats med dessa läkemedel. Gruppen som behandlats med TNF-hämmare delades upp i 
dem som behandlades med en första-, eller en andra-, TNF-hämmare. Dessa fem grupper av 
behandlingsdefinierade patientgrupper jämfördes mot patienter som behandlats med preparat 
av den äldre sorten. Vi undersökte risken för cancer generellt, men även uppdelat på 
blodcancer, solida tumörer, skivepitelcancer i huden, samt malignt melanom i huden. Liksom 
i föregående studier så kontrollerade vi för potentiellt viktiga störfaktorer, såsom ålder, kön, 
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utbildningsnivå, samt olika mått på samsjuklighet, behandling och sjukvårdsutnyttjande, smat 
även sjukskrivning och förtidspension. Med undantag för en ökad risk för skivepitelcancer i 
huden bland de som hade behandlats med abatacept, fann vi ingen säker skillnad i cancerrisk 
mellan grupperna. När vi kontrasterade gruppen ledgångsreumatiker mot 
befolkningskontroller såg vi dock att dessa hade en något ökad risk för cancer generellt, i 
linje med tidigare studier. Vi drog slutsatsen att cancerrisken på kort-, och medellång sikt, 
med användning av dessa preparat förefaller inte vara ökad, möjligtvis med undantag för 
abatacept och skivepitelcancer i huden. 
Tidigare studier som går tillbaka ända till 1960-talet har konstant visat på en lägre risk för 
bröstcancer bland kvinnor med ledgångsreumatism. Dessa studier har dock aldrig försökt 
bena ut vad denna risk beror på.  I Studie IV försökte vi därför undersöka om vi fortsatt såg 
en minskad risk för bröstcancer i denna patientgrupp med beaktande av kända riskfaktorer för 
bröstcancer. Vi undersökte även om risken för att utveckla ledgångsreumatism bland kvinnor 
med bröstcancer avvek från den i övriga befolkningen. Då tidigare rapporter har pekat på en 
ökad risk för ledgångsreumatism bland kvinnor som behandlats med antihormonell 
bröstcancerbehandling, försökte vi även undersöka detta. Med hjälp av register så 
identifierade vi nyinsjuknade kvinnor med ledgångsreumatism, och matchade 
befolkningskontroller. I våra modeller tog vi förutom demografiska och socioekonomiska 
faktorer, även barnafödande och hormonell behandling (p-piller eller östrogensubstitution i 
samband med klimakteriet) i beaktning. Vi fann att risken för bröstcancer fortfarande var 
20% lägre bland kvinnor med ledgångsreumatism men vi kunde inte förklara denna skillnad 
genom skillnader i de faktorer vi kontrollerade för. Vi fann även att risken för att insjukna i 
ledgångsreumatism var lägre bland kvinnor med tidigare bröstcancer. Detta kan tyda på att 
det finns andra gemensamma faktorer mellan dessa sjukdomar, som vi inte har kontrollerat 
för, som medför en invers association mellan dessa och som inte har med själva sjukdomarna 
eller deras behandlingar att göra. Till slut fann vi också att i motsats till tidigare studier var 
antihormonell behandling mot bröstcancer inte förknippad med en ökad risk för att utveckla 
ledgångsreumatism. 
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